US20050171103A1 - Benzamide derivatives useful as histone deacetylase inhibitors - Google Patents
Benzamide derivatives useful as histone deacetylase inhibitors Download PDFInfo
- Publication number
- US20050171103A1 US20050171103A1 US10/509,941 US50994104A US2005171103A1 US 20050171103 A1 US20050171103 A1 US 20050171103A1 US 50994104 A US50994104 A US 50994104A US 2005171103 A1 US2005171103 A1 US 2005171103A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- amino
- optionally substituted
- group
- heterocyclic group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *.CC.CC.CC.[3*]C1=C(NC(=O)C2=CC=C(C)C=C2)C=CC=C1 Chemical compound *.CC.CC.CC.[3*]C1=C(NC(=O)C2=CC=C(C)C=C2)C=CC=C1 0.000 description 25
- UXQJXPJKLBSEOS-UHFFFAOYSA-N CC(C)(C)C1=CN=CC(N2CCNCC2)=N1 Chemical compound CC(C)(C)C1=CN=CC(N2CCNCC2)=N1 UXQJXPJKLBSEOS-UHFFFAOYSA-N 0.000 description 3
- CJGXJKVMUHXVHL-UHFFFAOYSA-N CC(C)(C)CC1=CC=CC=C1 Chemical compound CC(C)(C)CC1=CC=CC=C1 CJGXJKVMUHXVHL-UHFFFAOYSA-N 0.000 description 3
- FBXZCCMKKLTYBG-UHFFFAOYSA-N CCNC1=NC(NCC)=NC(C(C)(C)C)=N1 Chemical compound CCNC1=NC(NCC)=NC(C(C)(C)C)=N1 FBXZCCMKKLTYBG-UHFFFAOYSA-N 0.000 description 3
- VHEYNDDRMQXDEO-UHFFFAOYSA-N CN1C=NC2=C1N=CN=C2C(C)(C)C Chemical compound CN1C=NC2=C1N=CN=C2C(C)(C)C VHEYNDDRMQXDEO-UHFFFAOYSA-N 0.000 description 3
- XOPADLBBGXWNCV-UHFFFAOYSA-N CN1CCN(C2=NC(C(C)(C)C)=CC=N2)CC1 Chemical compound CN1CCN(C2=NC(C(C)(C)C)=CC=N2)CC1 XOPADLBBGXWNCV-UHFFFAOYSA-N 0.000 description 3
- BACYBRMSUXJYCE-UHFFFAOYSA-N *.CB(C)C.CC Chemical compound *.CB(C)C.CC BACYBRMSUXJYCE-UHFFFAOYSA-N 0.000 description 2
- KOWXKIHEBFTVRU-UHFFFAOYSA-N *.CC.CC Chemical compound *.CC.CC KOWXKIHEBFTVRU-UHFFFAOYSA-N 0.000 description 2
- XHUIGUOMZIKQDT-UHFFFAOYSA-N *.CC.CC.CC1=CC=C(C(=O)O)C=C1 Chemical compound *.CC.CC.CC1=CC=C(C(=O)O)C=C1 XHUIGUOMZIKQDT-UHFFFAOYSA-N 0.000 description 2
- SAXFODJHZMHNJZ-UHFFFAOYSA-N CC(=O)NC1=CC=C(OCCC(C)(C)C)C=C1 Chemical compound CC(=O)NC1=CC=C(OCCC(C)(C)C)C=C1 SAXFODJHZMHNJZ-UHFFFAOYSA-N 0.000 description 2
- PIALMVZEKRGGMK-UHFFFAOYSA-N CC(C)(C)C1=C2C=CSC2=NC=N1 Chemical compound CC(C)(C)C1=C2C=CSC2=NC=N1 PIALMVZEKRGGMK-UHFFFAOYSA-N 0.000 description 2
- DHPWMGFZIKOEQF-UHFFFAOYSA-N CC(C)(C)C1=C2SC=CC2=NC=C1 Chemical compound CC(C)(C)C1=C2SC=CC2=NC=C1 DHPWMGFZIKOEQF-UHFFFAOYSA-N 0.000 description 2
- GOZADGUHLYTWIO-UHFFFAOYSA-N CC(C)(C)C1=CC(NCCCN2CCOCC2)=NC=C1 Chemical compound CC(C)(C)C1=CC(NCCCN2CCOCC2)=NC=C1 GOZADGUHLYTWIO-UHFFFAOYSA-N 0.000 description 2
- YWOGVVKKQKNSFZ-UHFFFAOYSA-N CC(C)(C)C1=CC=NC(NCC2=CC=CN=C2)=N1 Chemical compound CC(C)(C)C1=CC=NC(NCC2=CC=CN=C2)=N1 YWOGVVKKQKNSFZ-UHFFFAOYSA-N 0.000 description 2
- QOPPWYNOEBUYJP-UHFFFAOYSA-N CC(C)(C)C1=CC=NC(NCCCN2CCCCC2)=N1 Chemical compound CC(C)(C)C1=CC=NC(NCCCN2CCCCC2)=N1 QOPPWYNOEBUYJP-UHFFFAOYSA-N 0.000 description 2
- QCELWUOANNRHDS-UHFFFAOYSA-N CC(C)(C)C1=CN=C(NCCCN2CCCCC2)N=C1 Chemical compound CC(C)(C)C1=CN=C(NCCCN2CCCCC2)N=C1 QCELWUOANNRHDS-UHFFFAOYSA-N 0.000 description 2
- RBFMXVBTXLBOGP-UHFFFAOYSA-N CC(C)(C)C1=CN=C(NCCCN2CCOCC2)N=C1 Chemical compound CC(C)(C)C1=CN=C(NCCCN2CCOCC2)N=C1 RBFMXVBTXLBOGP-UHFFFAOYSA-N 0.000 description 2
- LNCMCCNHEVRQNW-UHFFFAOYSA-N CC(C)(C)C1=CN=C(OCCN2CCCC2)N=C1 Chemical compound CC(C)(C)C1=CN=C(OCCN2CCCC2)N=C1 LNCMCCNHEVRQNW-UHFFFAOYSA-N 0.000 description 2
- PCAWUTFGCFMXJB-UHFFFAOYSA-N CC(C)(C)CC(=O)N1CCCC2=C1C=CC=C2 Chemical compound CC(C)(C)CC(=O)N1CCCC2=C1C=CC=C2 PCAWUTFGCFMXJB-UHFFFAOYSA-N 0.000 description 2
- SZCZOVFEZGIVPE-UHFFFAOYSA-N CC(C)(C)CC1CCCO1 Chemical compound CC(C)(C)CC1CCCO1 SZCZOVFEZGIVPE-UHFFFAOYSA-N 0.000 description 2
- XEMOVVGGJCBRCN-UHFFFAOYSA-N CC(C)(C)CCCN1CCOCC1 Chemical compound CC(C)(C)CCCN1CCOCC1 XEMOVVGGJCBRCN-UHFFFAOYSA-N 0.000 description 2
- UQZUDHIMZRVPRY-UHFFFAOYSA-N CC(C)(C)CCN1CCCCC1 Chemical compound CC(C)(C)CCN1CCCCC1 UQZUDHIMZRVPRY-UHFFFAOYSA-N 0.000 description 2
- HEYQFUYZTIKUSX-ZETCQYMHSA-N CC(C)(C)C[C@@H]1CCC(=O)N1 Chemical compound CC(C)(C)C[C@@H]1CCC(=O)N1 HEYQFUYZTIKUSX-ZETCQYMHSA-N 0.000 description 2
- ZJCDWOUMVLJAFP-UHFFFAOYSA-N CC.CC(C)(C)OC(=O)NC1=CC=CC=C1N Chemical compound CC.CC(C)(C)OC(=O)NC1=CC=CC=C1N ZJCDWOUMVLJAFP-UHFFFAOYSA-N 0.000 description 2
- XLIAVMCDSHBWSZ-UHFFFAOYSA-N CCN(CC)C1=CC=C(C(=O)CC(C)(C)C)C=C1 Chemical compound CCN(CC)C1=CC=C(C(=O)CC(C)(C)C)C=C1 XLIAVMCDSHBWSZ-UHFFFAOYSA-N 0.000 description 2
- SJFLPWJQADGWNL-UHFFFAOYSA-N CCN(CC)CCNC1=NC(C(C)(C)C)=CC=N1 Chemical compound CCN(CC)CCNC1=NC(C(C)(C)C)=CC=N1 SJFLPWJQADGWNL-UHFFFAOYSA-N 0.000 description 2
- HZBWTNTVCQOKEN-UHFFFAOYSA-N CN1CCN(CCCC(C)(C)C)CC1 Chemical compound CN1CCN(CCCC(C)(C)C)CC1 HZBWTNTVCQOKEN-UHFFFAOYSA-N 0.000 description 2
- DXBOTVWRXLQVMG-UHFFFAOYSA-N COC(=O)CC(C)(C)C Chemical compound COC(=O)CC(C)(C)C DXBOTVWRXLQVMG-UHFFFAOYSA-N 0.000 description 2
- BOCDYDPRUSDTNV-UHFFFAOYSA-N C1=CC=C(NCCCN2CCOCC2)N=C1 Chemical compound C1=CC=C(NCCCN2CCOCC2)N=C1 BOCDYDPRUSDTNV-UHFFFAOYSA-N 0.000 description 1
- AVXZMWDBEBBNOE-UHFFFAOYSA-N CC(=O)OCCC(C)(C)C Chemical compound CC(=O)OCCC(C)(C)C AVXZMWDBEBBNOE-UHFFFAOYSA-N 0.000 description 1
- IGUAHZPOJXKTOM-UHFFFAOYSA-N CC(C)(C)C1=CC=NC(NCCCN2C=CN=C2)=N1 Chemical compound CC(C)(C)C1=CC=NC(NCCCN2C=CN=C2)=N1 IGUAHZPOJXKTOM-UHFFFAOYSA-N 0.000 description 1
- OFMUFDQAVNBQFA-UHFFFAOYSA-N CC(C)(C)C1=CC=NC(NCCN2CCCCC2)=N1 Chemical compound CC(C)(C)C1=CC=NC(NCCN2CCCCC2)=N1 OFMUFDQAVNBQFA-UHFFFAOYSA-N 0.000 description 1
- HLJQILUCICUCKI-UHFFFAOYSA-N CC(C)(C)C1=CC=NC(OCCCN2CCOCC2)=C1 Chemical compound CC(C)(C)C1=CC=NC(OCCCN2CCOCC2)=C1 HLJQILUCICUCKI-UHFFFAOYSA-N 0.000 description 1
- SHAGHWPAASNGIW-UHFFFAOYSA-N CC(C)(C)C1=NC(NCCCN2CCCCC2)=NC2=C1SC=C2 Chemical compound CC(C)(C)C1=NC(NCCCN2CCCCC2)=NC2=C1SC=C2 SHAGHWPAASNGIW-UHFFFAOYSA-N 0.000 description 1
- PQHUSRRDAACFIF-UHFFFAOYSA-N CC(C)(C)C1=NC(NCCCN2CCOCC2)=NC2=C1SC=C2 Chemical compound CC(C)(C)C1=NC(NCCCN2CCOCC2)=NC2=C1SC=C2 PQHUSRRDAACFIF-UHFFFAOYSA-N 0.000 description 1
- OUFGIAAZKOICGT-UHFFFAOYSA-N CC(C)(C)C1=NC(NCCN2CCCCC2)=NC2=C1SC=C2 Chemical compound CC(C)(C)C1=NC(NCCN2CCCCC2)=NC2=C1SC=C2 OUFGIAAZKOICGT-UHFFFAOYSA-N 0.000 description 1
- MISPUAAYZDJDKM-UHFFFAOYSA-N CC(C)(C)C1=NC=C(COC(=O)NC2=CC=CC=C2)S1 Chemical compound CC(C)(C)C1=NC=C(COC(=O)NC2=CC=CC=C2)S1 MISPUAAYZDJDKM-UHFFFAOYSA-N 0.000 description 1
- WXYWMCVLYHRVHV-UHFFFAOYSA-N CC(C)(C)C1=NC=C(COC(=O)NC2CCCCC2)S1 Chemical compound CC(C)(C)C1=NC=C(COC(=O)NC2CCCCC2)S1 WXYWMCVLYHRVHV-UHFFFAOYSA-N 0.000 description 1
- PMWSLZOYRDSUGC-UHFFFAOYSA-N CC(C)(C)C1=NC=NC2=C1SC=C2 Chemical compound CC(C)(C)C1=NC=NC2=C1SC=C2 PMWSLZOYRDSUGC-UHFFFAOYSA-N 0.000 description 1
- ZYZSWBBICZDESI-UHFFFAOYSA-N CC(C)(C)CC(O)C1=CC2=CC=CC=C2C=C1 Chemical compound CC(C)(C)CC(O)C1=CC2=CC=CC=C2C=C1 ZYZSWBBICZDESI-UHFFFAOYSA-N 0.000 description 1
- NKKWYENCEXCGLD-UHFFFAOYSA-N CC(C)(C)CC(O)CO Chemical compound CC(C)(C)CC(O)CO NKKWYENCEXCGLD-UHFFFAOYSA-N 0.000 description 1
- BHJTUJPQDXHQHH-UHFFFAOYSA-N CC(C)(C)CC1=CC=C(C#N)C=C1 Chemical compound CC(C)(C)CC1=CC=C(C#N)C=C1 BHJTUJPQDXHQHH-UHFFFAOYSA-N 0.000 description 1
- BFHCJXWIFVPPQR-UHFFFAOYSA-N CC(C)(C)CC1=CC=CC(C#N)=C1 Chemical compound CC(C)(C)CC1=CC=CC(C#N)=C1 BFHCJXWIFVPPQR-UHFFFAOYSA-N 0.000 description 1
- KNDJNVWEKSLWOV-UHFFFAOYSA-N CC(C)(C)CC1=CC=CC=N1 Chemical compound CC(C)(C)CC1=CC=CC=N1 KNDJNVWEKSLWOV-UHFFFAOYSA-N 0.000 description 1
- RQHPEPIGRLVQKS-UHFFFAOYSA-N CC(C)(C)CC1=CC=CN=C1 Chemical compound CC(C)(C)CC1=CC=CN=C1 RQHPEPIGRLVQKS-UHFFFAOYSA-N 0.000 description 1
- AAZLQGXRTOHONH-UHFFFAOYSA-N CC(C)(C)CC1=NSN=C1 Chemical compound CC(C)(C)CC1=NSN=C1 AAZLQGXRTOHONH-UHFFFAOYSA-N 0.000 description 1
- IHDCOPXVKLXBIY-UHFFFAOYSA-N CC(C)(C)CC1CCCCO1 Chemical compound CC(C)(C)CC1CCCCO1 IHDCOPXVKLXBIY-UHFFFAOYSA-N 0.000 description 1
- JRRWPSIWFLGPJZ-UHFFFAOYSA-N CC(C)(C)CCC(=O)NC1=CC=CC=C1F Chemical compound CC(C)(C)CCC(=O)NC1=CC=CC=C1F JRRWPSIWFLGPJZ-UHFFFAOYSA-N 0.000 description 1
- IBDZOIPJLXXOMH-UHFFFAOYSA-N CC(C)(C)CCCCOCC1=CC=CC=C1 Chemical compound CC(C)(C)CCCCOCC1=CC=CC=C1 IBDZOIPJLXXOMH-UHFFFAOYSA-N 0.000 description 1
- DFUHHIUBQQKKFL-UHFFFAOYSA-N CC(C)(C)CCCN1C=CC=C1 Chemical compound CC(C)(C)CCCN1C=CC=C1 DFUHHIUBQQKKFL-UHFFFAOYSA-N 0.000 description 1
- FXDXBWUOAXOYEA-UHFFFAOYSA-N CC(C)(C)CCCN1C=CN=C1 Chemical compound CC(C)(C)CCCN1C=CN=C1 FXDXBWUOAXOYEA-UHFFFAOYSA-N 0.000 description 1
- AFZRHAXRDREZTQ-UHFFFAOYSA-N CC(C)(C)CCCNC(=O)OC(C)(C)C Chemical compound CC(C)(C)CCCNC(=O)OC(C)(C)C AFZRHAXRDREZTQ-UHFFFAOYSA-N 0.000 description 1
- NKHWGFXIULJDDH-UHFFFAOYSA-N CC(C)(C)CCCOCC1=CC=CC=C1 Chemical compound CC(C)(C)CCCOCC1=CC=CC=C1 NKHWGFXIULJDDH-UHFFFAOYSA-N 0.000 description 1
- FHVZZKSFYWTRHS-UHFFFAOYSA-N CC(C)(C)CCNC(=O)OC(C)(C)C Chemical compound CC(C)(C)CCNC(=O)OC(C)(C)C FHVZZKSFYWTRHS-UHFFFAOYSA-N 0.000 description 1
- ZFLAFKHGVKHETR-UHFFFAOYSA-N CC(C)(C)CCOC1=CC=C(Cl)C=C1 Chemical compound CC(C)(C)CCOC1=CC=C(Cl)C=C1 ZFLAFKHGVKHETR-UHFFFAOYSA-N 0.000 description 1
- PAICIFFQRSBOLE-UHFFFAOYSA-N CC(C)(C)CCOC1=CC=C(O)C=C1 Chemical compound CC(C)(C)CCOC1=CC=C(O)C=C1 PAICIFFQRSBOLE-UHFFFAOYSA-N 0.000 description 1
- MMFKTXRNRDZDAA-UHFFFAOYSA-N CC(C)(C)CCOC1=CC=C([N+](=O)[O-])C=C1 Chemical compound CC(C)(C)CCOC1=CC=C([N+](=O)[O-])C=C1 MMFKTXRNRDZDAA-UHFFFAOYSA-N 0.000 description 1
- ZBISMGLJTXKLQV-UHFFFAOYSA-N CC(C)(C)CCOC1=CC=CC=C1 Chemical compound CC(C)(C)CCOC1=CC=CC=C1 ZBISMGLJTXKLQV-UHFFFAOYSA-N 0.000 description 1
- PJDUNKKHPCBOPA-UHFFFAOYSA-N CC(C)=CCCC(C)(C)C Chemical compound CC(C)=CCCC(C)(C)C PJDUNKKHPCBOPA-UHFFFAOYSA-N 0.000 description 1
- UNSFKPRPICHULQ-UHFFFAOYSA-N CC1=CC=C(C(C)(C)C)C=N1 Chemical compound CC1=CC=C(C(C)(C)C)C=N1 UNSFKPRPICHULQ-UHFFFAOYSA-N 0.000 description 1
- AFTPEBDOGXRMNQ-UHFFFAOYSA-N CCC(C)CC(C)(C)C Chemical compound CCC(C)CC(C)(C)C AFTPEBDOGXRMNQ-UHFFFAOYSA-N 0.000 description 1
- VZKMEFLWLDDCBI-UHFFFAOYSA-N CCCCN(CCCC)CCNC1=NC(C(C)(C)C)=CC=N1 Chemical compound CCCCN(CCCC)CCNC1=NC(C(C)(C)C)=CC=N1 VZKMEFLWLDDCBI-UHFFFAOYSA-N 0.000 description 1
- YLFPJTVGQKBXIZ-UHFFFAOYSA-N CCN(CC)CCC(C)(C)C Chemical compound CCN(CC)CCC(C)(C)C YLFPJTVGQKBXIZ-UHFFFAOYSA-N 0.000 description 1
- LYKXUOXVKIEYPV-UHFFFAOYSA-N CCN(CC)CCCCC(C)(C)C Chemical compound CCN(CC)CCCCC(C)(C)C LYKXUOXVKIEYPV-UHFFFAOYSA-N 0.000 description 1
- ADYACJFXPZEZRI-UHFFFAOYSA-N CCN(CC)CCCCNC1=NC(C(C)(C)C)=CC=N1 Chemical compound CCN(CC)CCCCNC1=NC(C(C)(C)C)=CC=N1 ADYACJFXPZEZRI-UHFFFAOYSA-N 0.000 description 1
- XSAZOMKKFXIWTR-UHFFFAOYSA-N CCN(CC)CCCNC1=NC=C(C(C)(C)C)C=N1.CN1CCN(CCCNC2=NC=C(C(C)(C)C)C=N2)CC1 Chemical compound CCN(CC)CCCNC1=NC=C(C(C)(C)C)C=N1.CN1CCN(CCCNC2=NC=C(C(C)(C)C)C=N2)CC1 XSAZOMKKFXIWTR-UHFFFAOYSA-N 0.000 description 1
- SQNRAWDGGCHKFN-UHFFFAOYSA-N CCOCCC(C)(C)C Chemical compound CCOCCC(C)(C)C SQNRAWDGGCHKFN-UHFFFAOYSA-N 0.000 description 1
- VMQVMSCPIRCOKW-UHFFFAOYSA-N CN(CCCNC1=NC(C(C)(C)C)=CC=N1)C1=CC=CC=C1 Chemical compound CN(CCCNC1=NC(C(C)(C)C)=CC=N1)C1=CC=CC=C1 VMQVMSCPIRCOKW-UHFFFAOYSA-N 0.000 description 1
- IPVDYQIODRKFFC-UHFFFAOYSA-N CN1CCN(CCCNC2=NC(C(C)(C)C)=CC=N2)CC1 Chemical compound CN1CCN(CCCNC2=NC(C(C)(C)C)=CC=N2)CC1 IPVDYQIODRKFFC-UHFFFAOYSA-N 0.000 description 1
- WCLLZPXEKMITQZ-UHFFFAOYSA-N COC1=C(OCCC(C)(C)C)C=CC=C1 Chemical compound COC1=C(OCCC(C)(C)C)C=CC=C1 WCLLZPXEKMITQZ-UHFFFAOYSA-N 0.000 description 1
- GMYZXSUHBAJAPU-UHFFFAOYSA-N COC1=CC=CC(CC(C)(C)C)=C1 Chemical compound COC1=CC=CC(CC(C)(C)C)=C1 GMYZXSUHBAJAPU-UHFFFAOYSA-N 0.000 description 1
- QLBMHQYMMVSBPC-UHFFFAOYSA-N COCCCC(C)(C)C Chemical compound COCCCC(C)(C)C QLBMHQYMMVSBPC-UHFFFAOYSA-N 0.000 description 1
- HELITNPDGUSYJD-UHFFFAOYSA-N COCCCNC1=NC(C(C)(C)C)=CC=N1 Chemical compound COCCCNC1=NC(C(C)(C)C)=CC=N1 HELITNPDGUSYJD-UHFFFAOYSA-N 0.000 description 1
- LOJYGXJSZPYFJW-UHFFFAOYSA-N COCCOCCCC(C)(C)C Chemical compound COCCOCCCC(C)(C)C LOJYGXJSZPYFJW-UHFFFAOYSA-N 0.000 description 1
- YIEVGELYYUMOKA-UHFFFAOYSA-N CSC1=NC(C(C)(C)C)=C2SC=CC2=N1 Chemical compound CSC1=NC(C(C)(C)C)=C2SC=CC2=N1 YIEVGELYYUMOKA-UHFFFAOYSA-N 0.000 description 1
- OWMWFZLXNDKVBJ-UHFFFAOYSA-N CSC1=NC=CC(C2=CC=C(C(C)(C)C)S2)=N1 Chemical compound CSC1=NC=CC(C2=CC=C(C(C)(C)C)S2)=N1 OWMWFZLXNDKVBJ-UHFFFAOYSA-N 0.000 description 1
- LTERVRRIQZYVDJ-UHFFFAOYSA-N NC1=CC=CC=C1NC(=O)C1=CC=C(C2=NC=C(COC(=O)NC3=CC=CC=C3)S2)C=C1 Chemical compound NC1=CC=CC=C1NC(=O)C1=CC=C(C2=NC=C(COC(=O)NC3=CC=CC=C3)S2)C=C1 LTERVRRIQZYVDJ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
- C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
- C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- This invention relates to benzamide derivatives, or pharmaceutically acceptable salts or in vivo hydrolysable esters or amides thereof.
- These benzamide derivatives possess histone deacetylase (HDAC) inhibitory activity and accordingly have value in the treatment of disease states associated with cancer (Marks et al., Nature Reviews, 1, 194-202, (2001)), cystic fibrosis (Li, S. et al, J. Biol. Chem., 274, 7803-7815, (1999)), Huntingdons chorea (Steffan, J. S. et al., Nature, 413, 739-743, (2001)) and sickle cell anaemia (Gabbianelli, M.
- HDAC histone deacetylase
- the invention also relates to processes for the manufacture of said benzamide derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments to inhibit HDAC in a warm-blooded animal, such as man.
- DNA is compacted to prevent transcription factor accessibility.
- this compact DNA is made available to DNA-binding proteins, thereby allowing the induction of gene transcription (Beato, M., J. Med. Chem., 74, 711-724 (1996); Wolffe, A. P., Nature, 387, 16-17 (1997)).
- Nuclear DNA associates with histones to form a complex known as chromatin.
- the core histones termed H2A, H2B, H3 and H4 surrounded by 146 base pairs of DNA form the fundamental unit of chromatin, the nucleosome.
- the N-terminal tails of the core histones contain lysines that are sites for post-transcriptional acetylation. Acetylation neutralizes the potential of the side chain to form a positive charge on the lysine side chain, and is thought to impact chromatin structure.
- Histone Deacetylases are zinc-containing enzymes which catalyse the removal of acetyl groups from the ⁇ -amino termini of lysine residues clustered near the amino terminus of nucleosomal histones.
- HDACs may be divided into two classes, the first (HDAC 1, 2, 3 and 8) represented by yeast Rpd3-like proteins, and the second (HDAC 4, 5, 6, 7, 9 and 10) represented by yeast Hda1-like proteins.
- the reversible process of acetylation is important in transcriptional regulation and cell-cycle progression.
- HDAC deregulation has been associated with several cancers and HDAC inhibitors, such as Trichostatin A (a natural product isolated from Streptomyces hygroscopicus ), have been shown to exhibit significant anti-tumour effects and inhibition of cell-growth (Meinke, P. T., Current Medicinal Chemistry, 8, 211-235 (2001)). Yoshida et al, Exper. Cell Res., 177, 122-131 (1988) teaches that Trichostatin A causes arrest of rat fibroblasts at the G1 and G2 phases of the cell cycle, thereby implicating HDAC in cell cycle regulation. Furthermore, Trichostatin A has been shown to induce terminal differentiation, inhibit cell growth, and prevent the formation of tumours in mice (Finnin et al., Nature, 401, 188-193 (1999)).
- Trichostatin A a natural product isolated from Streptomyces hygroscopicus
- alkyl includes both straight and branched chain alkyl groups.
- C 1-8 alkyl and “C 1-6 alkyl” includes methyl, ethyl, propyl, isopropyl, pentyl, hexyl, heptyl, and t-butyl.
- references to individual alkyl groups such as ‘propyl’ are specific for the straight-chained version only and references to individual branched chain alkyl groups such as ‘isopropyl’ are specific for the branched chain version only.
- halo refers to fluoro, chloro, bromo and iodo.
- a “heterocyclyl” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a ring sulphur atom may be optionally oxidised to form the S-oxide(s).
- a “heterocyclyl” is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen or a 8-10 membered bicyclic ring which may, unless otherwise specified, be carbon or nitrogen linked, wherein a ring sulphur atom may be optionally oxidised to form S-oxide(s).
- heterocyclyl examples and suitable values of the term “heterocyclyl” are thiazolidinyl, pyrrolidinyl, 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, morpholinyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl, 1,3-dioxolanyl, homopiperazinyl, thienyl, pyrrolyl, pyrazolyl, oxadiazolyl, tetrazolyl, oxazolyl, thienopyrimidinyl, thienopyridinyl, thieno[3,2d]pyrimidinyl, 1,3,5-triazinyl, purinyl, 1,2,3,4-tetrahydroquinolinyl, benzimid
- a “heterocyclic group” is a saturated, partially saturated or unsaturated, mono or bicyclic ring containing 3-12 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen, which may, unless otherwise specified, be carbon or nitrogen linked, wherein a CH 2 group can optionally be replaced by a C(O), and wherein a ring sulphur atom may be optionally oxidised to form the S-oxide(s).
- a “heterocyclic group” is a saturated, partially saturated or unsaturated, monocyclic ring containing 5 or 6 atoms of which at least one atom is chosen from nitrogen, sulphur or oxygen or a 9 or 10 membered bicyclic ring which may, unless otherwise specified, be carbon or nitrogen linked, wherein a CH 2 group can optionally be replaced by a C(O), and wherein a ring sulphur atom may be optionally oxidised to form S-oxide(s).
- heterocyclic group examples and suitable values of the term “heterocyclic group” are pyrrolidinyl, 2-pyrrolidonyl 2,5-dioxopyrrolidinyl, 2,4-dioxoimidazolidinyl, 2-oxo-1,3,4-triazolinyl, oxazolidinyl, 2-oxazolidonyl, 5,6-dihydro-uracilyl, 1,3-benzodioxolyl, 1,2,4-oxadiazolyl, 2-azabicyclo[2.2.1]heptyl, morpholinyl, 2-oxotetrahydrofuranyl, tetrahydrofuranyl, furanyl, tetrahydropyranyl, piperidinyl, piperazinyl, thiomorpholinyl, 1,1-dioxothiomorpholinyl, 1,3-dioxolanyl, homopiperazinyl, thiophenyl
- aryl is, for example, phenyl, indenyl, indanyl, naphthyl, tetrahydronaphthyl or fluorenyl, preferably phenyl.
- C 1-6 alkanoyloxy is acetoxy.
- Examples of “C 1-8 alkoxycarbonyl”, “C 1-6 alkoxycarbonyl” and C 1-4 alkoxycarbonyl include methoxycarbonyl, ethoxycarbonyl, n- and t-butoxycarbonyl.
- Examples of C 2-6 alkynyl are ethynyl and 2-propynyl.
- Examples of “C 1-6 alkoxy” include methoxy, ethoxy and propoxy.
- Examples of “C 1-6 alkanoylamino” and C 1-3 alkanoylamino include formamido, acetamido and propionylamino.
- C 1-6 alkylS(O) a wherein a is 0 to 2 include C 1-4 alkylsulphonyl, C 1-3 alkylS(O) a , methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl and ethylsulphonyl.
- Examples of “C 1-8 alkanoyl”, “C 1-6 alkanoyl” and C 1-4 alkanoyl include C 1-3 alkanoyl, propionyl and acetyl.
- N—C 1-6 alkylamino and N—(C 1-3 alkyl)amino include methylamino and ethylamino.
- Examples of “N,N—(C 1-6 alkyl) 2 amino” and N,N—(C 1-2 alkyl) 2 amino include di-N-methylamino, di-(N-ethyl)amino, di-(N-butyl)amino and N-ethyl-N-methylamino.
- Examples of “C 2-8 alkenyl” are C 2-6 alkenyl and C 2-3 alkenyl, and include vinyl, allyl, and 1-propenyl.
- N—(C 1-8 alkyl)sulphamoyl and“N—(C 1-6 alkyl)sulphamoyl” are N—(C 1-3 alkyl)sulphamoyl, N-(methyl)sulphamoyl and N-(ethyl)sulphamoyl.
- N—(C 1-6 alkyl) 2 sulphamoyl are N,N—(C 1-3 alkyl) 2 sulphamoyl, N,N-(dimethyl)sulphamoyl and N-(methyl)-N-(ethyl)sulphamoyl.
- N—(C 1-8 alkyl)carbamoyl and “N—(C 1-6 alkyl)carbamoyl” are N—(C 1-4 alkyl)carbamoyl, N—(C 1-3 alkyl)carbamoyl, methylaminocarbonyl, and ethylaminocarbonyl.
- N,N—(C 1-8 alkyl) 2 carbamoyl and “N,N—(C 1-6 alkyl) 2 carbamoyl” are N,N—(C 1-4 alkyl)carbamoyl, N,N—(C 1-2 alkyl) 2 carbamoyl, dimethylaminocarbonyl and methylethylaminocarbonyl.
- Examples of “(heterocyclic group)C 1-6 alkyl” include piperidin-1-ylmethyl, piperidin-1-ylethyl, piperdin-1-ylpropyl, pyridylmethyl, 3-morpholinopropyl, 2-morpholinoethyl and 2-pyrimid-2-ylethyl.
- Examples of “(heterocyclic group)C 1-6 -alkoxy” include (heterocyclic group)methoxy, (heterocyclic group)ethoxy and (heterocyclic group)propoxy.
- Examples of “arylC 1-6 alkyl” include benzyl, 2-phenylethyl, 2-phenylpropyl and 3-phenylpropyl Examples of “aryloxy” include phenoxy and naphthyloxy.
- Examples of “C 3-8 cycloalkyl” include cyclopropyl and cyclohexyl.
- Examples of “C 3-8 cycloalkylC 1-6 alkyl” include cyclopropylmethyl and 2-cyclohexylpropyl.
- Examples of “C 1-6 alkoxycarbonylamino” include methoxycarbonylamino and t-butoxycarbonylamino.
- arylC 1-6 alkyl comprises C 1-6 alkyl substituted by aryl and such a group includes benzyl, 2-phenylethyl, 2-phenylpropyl and 3-phenylpropyl.
- a suitable pharmaceutically acceptable salt of a compound of the invention is, for example, an acid-addition salt of a compound of the invention which is sufficiently basic, for example, an acid-addition salt with, for example, an inorganic or organic acid, for example acetic, hydrochloric, hydrobromic, sulphuric, phosphoric, trifluoroacetic, citric or maleic acid.
- a suitable pharmaceutically acceptable salt of a compound of the invention which is sufficiently acidic is an alkali metal salt, for example a sodium or potassium salt, an alkaline earth metal salt, for example a calcium or magnesium salt, an ammonium salt or a salt with an organic base which affords a physiologically-acceptable cation, for example a salt with metetylamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.
- the compounds of the formula (I) may be administered in the form of an in vivo hydrolysable ester or in vivo hydrolysable amide of a compound of the formula (I).
- An in vivo hydrolysable ester of a compound of the formula (I) containing carboxy or hydroxy group is, for example, a pharmaceutically acceptable ester which is hydrolysed in the human or animal body to produce the parent acid or alcohol.
- Suitable pharmaceutically acceptable esters for carboxy include C 1-6 alkoxymethyl esters for example methoxymethyl, C 1-6 alkanoyloxymethyl esters for example pivaloyloxymethyl, phthalidyl esters, C 3-8 cycloalkoxycarbonyloxyC 1-6 alkyl esters for example 1-cyclohexylcarbonyloxyethyl; 1,3-dioxolen-2-onylmethyl esters for example 5-methyl-1,3-dioxolen-2-onylmethyl; and C 1-6 -alkoxycarbonyloxyethyl esters for example 1-methoxycarbonyloxyethyl and may be formed at any carboxy group in the compounds of this invention.
- An in vivo hydrolysable ester of a compound of the formula (I) containing a hydroxy group includes inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
- inorganic esters such as phosphate esters and ⁇ -acyloxyalkyl ethers and related compounds which as a result of the in vivo hydrolysis of the ester breakdown to give the parent hydroxy group.
- ⁇ -acyloxyalkyl ethers include acetoxymethoxy and 2,2-dimethylpropionyloxy-methoxy.
- a selection of in vivo hydrolysable ester forming groups for hydroxy include alkanoyl, benzoyl, phenylacetyl and substituted benzoyl and phenylacetyl, alkoxycarbonyl (to give alkyl carbonate esters), dialkylcarbamoyl and N—(N,N-dialkylaminoethyl)-N-alkylcarbamoyl (to give carbamates), N,N-dialkylaminoacetyl and carboxyacetyl.
- substituents on benzoyl include morpholino and piperazino linked from a ring nitrogen atom via a methylene group to the 3- or 4-position of the benzoyl ring.
- a suitable value for an in vivo hydrolyzable amide of a compound of the formula (I) containing a carboxy group is, for example, a N—C 1-6 alkyl or N,N-di-C 1-6 alkyl amide such as N-methyl, N-ethyl, N-propyl, N,N-dimethyl, N-ethyl-N-methyl or N,N-diethyl amide.
- Some compounds of the formula (I) may have chiral centres and/or geometric isomeric centres (E- and Z-isomers), and it is to be understood that the invention encompasses all such optical, diastereoisomers and geometric isomers that possess HDAC inhibitory activity.
- the invention relates to any and all tautomeric forms of the compounds of the formula (I) that possess HDAC inhibitory activity.
- Ring A R 1 , R 2 , R 3 , R 4 , m, n and p are as follows. Such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.
- Ring A is a pyridyl, quinolyl, indolyl, pyrimidinyl, morpholinyl, piperidinyl, piperazinyl, pyradazinyl, pyrazinyl, thiazolyl, thienyl, thienopyrimidinyl, thienopyridinyl, purinyl, triazinyl, oxazolyl, pyrazolyl, or furanyl; wherein if Ring A contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from K.
- Ring A is pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, quinolin-8-yl, pyrimidin-6-yl, pyrimidin-5-yl, pyrimidin-4-yl, morpholin-4-yl, piperidin-4-yl, piperidin-3-yl, piperdin-2-yl, piperazin-4-yl, pyridazin-5-yl, pyrazin-6-yl, thiazol-2-yl, thien-2-yl, thieno[3,2d]pyrimidinyl, thieno[3,2b]pyrimidinyl, thieno[3,2b]pyridinyl, purin-6-yl or triazin-6-yl; wherein if Ring A contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from K.
- Ring A is a pyridyl, quinolyl, pyrimidyl, morpholinyl, piperidinyl, piperazinyl, pyradazinyl, pyrazinyl, thiazyl or furanyl.
- Ring A is a pyridin-4-yl, pyridin-3-yl, pyridin-2-yl, quinoline-8-yl, pyradizin-2-yl, furan-3-yl, morpholinyl, thiazol-2-yl, pyrimidin-6-yl, piperidin-4-yl or piperazin-4-yl.
- Ring A is pyridin-4-yl, pyridin-3-yl, quinoline-8-yl, piperidin-4-yl or piperazin-4-yl.
- R 1 is a substituent on carbon and is selected from halo, amino, C 1-6 alkyl, C 1-6 alkoxy, N—(C 1-6 alkyl)amino, aryl, aryloxy, arylC 1-6 alkyl, heterocyclic group, (heterocyclic group)C 1-6 alkyl, or a group (B-E-); wherein R 1 , including group (B-E-), may be optionally substituted on carbon by one or more W; and wherein if said heterocyclic group contains an —NH— moiety that nitrogen may be optionally substituted by J;
- W is hydroxy, mercapto, C 1-6 alkyl, C 1-6 alkoxy, N,N—(C 1-6 alkyl) 2 amino or a group (B′-E′-); wherein W, including group (B′-E′-), may be optionally substituted on carbon by one or more Y;
- Y and Z are independently selected from halo, nitro, cyano, hydroxy, C 1-6 alkoxy, N,N—(C 1-6 alkyl) 2 amino or C 1-6 alkanoylamino;
- G, J and K are independently selected from C 1-8 alkyl, C 2-8 alkenyl, C 1-8 alkanoyl, aryl, arylC 1-6 alkyl or (heterocyclic group)C 1-6 alkyl; wherein G, J and K may be optionally substituted on carbon by one or more Q; and wherein if said heterocyclic group contains an —NH— moiety that nitrogen may be optionally substituted by hydrogen or C 1-6 alkyl;
- Q is cyano, hydroxy, C 1-6 alkoxy, C 1-6 alkanoyloxy, C 1-6 alkoxycarbonyl, C 1-6 alkoxycarbonylamino, aryl, aryloxy or a group (B′′-E′′-); wherein Q, including group (B′′-E′′-), maybe optionally substituted on carbon by one or more Z;
- B, B′ and B′′ are independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 3-8 cycloalkyl, C 3-8 cycloalkylC 1-6 alkyl, aryl, arylC 1-6 alkyl, heterocyclic group, (heterocyclic group)C 1-6 alkyl, phenyl or phenylC 1-6 alkyl; wherein B, B′ and B′′ may be optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from G;
- E, E′ and E′′ are independently selected from —N(R a )—, —O—, —C(O)O—, —OC(O)—, —C(O)—, —N(R a )C(O)—, —N(R a )C(O)N(R b )—, —N(R a )C(O)O—, —OC(O)N(R a )—, —C(O)N(R a )—, —S(O) r —, —SO 2 N(R a )—, —N(R a )SO 2 —; wherein R a and R b are independently selected from hydrogen or C 1-6 alkyl optionally substituted by one or more F and r is 0-2;
- D and F are independently selected from halo, C 1-6 alkoxy or N,N—(C 1-6 alkyl) 2 amino.
- R 1 is a substituent on carbon and is selected from fluoro, chloro, amino, methyl, ethyl, propyl, methoxy, N-methylamino, N-ethylamino, N-propylamino, N-butylamino, phenyl, naphthylethyl, piperizin-1-yl, piperdin-1-yl, piperdin-4-yl, 2-(thiomethyl)-pyrimidin-4-yl, tetrahydrofuran-2-ylmethyl, tetrahydropyran-2-ylmethyl, 1,2,5-thiadiazol-3-ylethyl, piperdin-1-ylmethyl, pyridin-2-ylmethyl, or a group (B-E-); wherein R 1 , including group (B-E-), may be optionally substituted on carbon by one or more W; and wherein if said heterocyclic group contains an —NH— moiety that nitrogen may be optionally substituted by J;
- W is hydroxy, methyl, ethyl, ethoxy, N,N-(diethyl)amino, N,N-(dibutyl)amino, or a group (B′-E′-); wherein W, including group (B′-E′-), may be optionally substituted on carbon by one or more Y;
- Y and Z are independently selected from fluoro, chloro, bromo, nitro, cyano hydroxy, methoxy, N,N-(dimethyl)amino or methylcarbonylamino;
- G, J and K are independently selected from methyl, ethyl, propyl, pentyl, 2-methylbutyl, butyl, acetyl, benzyl, 3-(pyrrol-1-yl)propyl or pyrrolidin-2-one-(5S)-methyl; wherein G, J and K may be optionally substituted on carbon by one or more Q; and wherein if said heterocyclic group contains an —NH— moiety that nitrogen may be optionally substituted by hydrogen or methyl;
- Q is cyano, hydroxy, methoxy, ethoxy, methylcarbonyloxy, methoxycarbonyl, t-butoxycarbonlyamino, phenyl or a group (B′′-E′′-); wherein Q, including group (B′′-E′′-), may be optionally substituted on carbon by one or more Z;
- B, B′ and B′′ are independently selected from methyl, ethyl, propyl, cyclohexyl, phenyl, benzyl, 1,2,3,4-tetrahydroquinolinyl, 3-morpholinopropyl, 2-morpholinoethyl, 2-pyrrolidin-1-ylethyl, 3-morpholinopropyl, 3-(4-methylpiperazin-1-yl)propyl, 2-piperidin-1-ylethyl, 3-piperidin-1-ylpropyl, pyridin-3-ylmethyl or imidazol-1-ylpropyl; wherein B, B′ and B′′ may be optionally substituted on carbon by one or more D; and wherein if said heterocyclic group contains an —NH— moiety that nitrogen may be optionally substituted by a group selected from G;
- E, E′ and E′′ are independently selected from —N(R a )—, —O—, —C(O)—, —NHC(O)—, —N(R a )C(O)O—; wherein R a is hydrogen or methyl optionally substituted by one or more F;
- D and F are independently selected from fluoro, methoxy or ethoxy.
- R 1 is fluoro, chloro, amino, methyl, methoxy, 3-morpholin-4-ylpropylamino, (3-morpholin-4-yl)ethylamino, acetyl, benzyl, methoxycarbonylmethyl, 2-pyrrolidin-1-ylethoxy, 3-morpholinopropoxy, N-(2-fluorophenyl)propanamide, 4-(diethylamino)phenylcarbonylmethyl, 3-(4-methylpiperazin-1-yl)propylamino, 2-piperidin-1-ylethylamino, 2-[N,N-(diethyl)amino]ethylamino, pyridin-3-ylmethylamino, 3-piperidin-1-ylpropylamino, imidazol-1-ylpropylamino, 3-methoxypropylamino, 3-morpholinopropylamino, piperazin-1-yl, N-ethylamino, 4-methyl
- R 1 is halo, amino, C 1-6 alkyl, C 1-6 alkoxy, C 1-3 alkanoyloxy, N—(C 1-3 alkyl)amino, N,N—(C 1-6 alkyl) 2 amino, C 1-3 alkanoylamino, N—(C 1-3 alkyl)carbamoyl, N,N—(C 1-3 alkyl) 2 carbamoyl.
- R 1 is halo, amino, C 1-6 alkyl or C 1-6 alkoxy.
- R 1 is halo, amino, methyl or methoxy.
- n 0, 1, 2, 3 or 4; wherein the values of R 1 may be the same or different.
- n 0, 1, or 2; wherein the values of R 1 may be the same or different.
- m 0 or 1.
- R 2 is halo
- R 2 is fluoro or chloro.
- R 2 is fluoro
- n 0, 1 or 2
- R 2 may be the same or different.
- n 0 or 1.
- n 0.
- n 1.
- R 3 is amino or hydroxy.
- R 3 is amino
- R 3 is hydroxy
- R 4 is halo, nitro, cyano, hydroxy, trifluoromethyl, trifluoromethoxy, amino, carboxy or carbamoyl.
- R 4 is halo, cyano, trifluoromethyl or trifluoromethoxy.
- R 4 is halo
- R 4 is 0, 1 or 2
- R 4 may be the same or different.
- p 0 or 1.
- preferred compounds of the invention are any one of the Examples, or a pharmaceutically acceptable salt or an in vivo hydrolysable ester or amide thereof.
- Another aspect of the present invention provides a process for preparing a compound of formula (I) or a pharmaceutically acceptable salt or an in vivo hydrolysable ester thereof which process (wherein Ring A, R 1 , R 2 , R 3 , R 4 , m, n and p are, unless otherwise specified, as defined in formula (I)) comprises of:
- a suitable base for process (a), (b) or (c) is, for example, an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N -methylmorpholine or diazabicyclo[5.4.0]undec-7-ene, or, for example, an alkali or alkaline earth metal carbonate or hydroxide, for example sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide or potassium hydroxide, or, for example, an alkali metal hydride, for example sodium hydride, or a metal alkoxide such as sodium ethoxide.
- an organic amine base such as, for example, pyridine, 2,6-lutidine, collidine, 4-dimethylaminopyridine, triethylamine, morpholine, N -methylmorpholine or diazabicyclo[5.4.0]undec-7-ene
- a suitable reactive group X is, for example, a halo, alkoxy, aryloxy or sulphonyloxy group, for example a chloro, bromo, methoxy, phenoxy, methanesulphonyloxy, trifluromethanesulphonyloxy or toluene-4-sulphonyloxy group.
- the reactions are conveniently carried out in the presence of a suitable inert solvent or diluent, for example an alkanol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloroform or carbon tetrachloride, an ether such as tetrahydrofuran, 1,2-dimethoxyethane or 1,4-dioxan, an aromatic solvent such as toluene, or a dipolar aprotic solvent such as N , N -dimethylformamide, N , N -dimethylacetamide, N -methylpyrrolidin-2-one or dimethylsulphoxide.
- a suitable inert solvent or diluent for example an alkanol or ester such as methanol, ethanol, isopropanol or ethyl acetate, a halogenated solvent such as methylene chloride, chloro
- a suitable value for the ligands L 1 and L 2 which are present on the boron atom include, for example, a hydroxy, (1-4C)alkoxy or (1-6C)alkyl ligand, for example a hydroxy, methoxy, ethoxy, propoxy, isopropoxy, butoxy, methyl, ethyl, propyl, isopropyl or butyl ligand.
- the ligands L 1 and L 2 may be linked such that, together with the boron atom to which they are attached, they form a ring.
- L 1 and L 2 together may define an oxy-(2-4C)alkylene-oxy group, for example an oxyethyleneoxy or oxytrimethyleneoxy group such that, together with the boron atom to which they are attached, they form a cyclic boronic acid ester group;
- a suitable catalyst for process (a) or (b) includes, for example, a metallic catalyst such as a palladium(0), palladium(II), nickel(0) or nickel(II) catalyst, for example tetrakis(triphenylphosphine)palladium(0), palladium(II) chloride, palladium(II) bromide, bis(triphenylphosphine)palladium(II) chloride, tetrakis(triphenylphosphine)nickel(0), nickel(II) chloride, nickel(II) bromide or bis(triphenylphosphine)nickel(II) chloride.
- a free radical initiator may conveniently be added, for example an azo compound such as azo(bisisobutyronitrile);
- aromatic substitution reactions include the introduction of a nitro group using concentrated nitric acid, the introduction of an acyl group using, for example, an acyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; the introduction of an alkyl group using an alkyl halide and Lewis acid (such as aluminium trichloride) under Friedel Crafts conditions; and the introduction of a halo group.
- modifications include the reduction of a nitro group to an amino group by for example, catalytic hydrogenation with a nickel catalyst or treatment with iron in the presence of hydrochloric acid with heating; oxidation of alkylthio to alkylsulphinyl or alkylsulphonyl.
- a suitable protecting group for an amino or alkylamino group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an alkoxycarbonyl group, for example a methoxycarbonyl, ethoxycarbonyl or t-butoxycarbonyl group, an arylmethoxycarbonyl group, for example benzyloxycarbonyl, or an aroyl group, for example benzoyl.
- the deprotection conditions for the above protecting groups necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or alkoxycarbonyl group or an aroyl group may be removed for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- an acyl group such as a t-butoxycarbonyl group may be removed, for example, by treatment with a suitable acid as hydrochloric, sulphuric or phosphoric acid or trifluoroacetic acid and an arylmethoxycarbonyl group such as a benzyloxycarbonyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon, or by treatment with a Lewis acid for example boron tris(trifluoroacetate).
- a suitable alternative protecting group for a primary amino group is, for example, a phthaloyl group which may be removed by treatment with an alkylamine, for example dimethylaminopropylamine, or with hydrazine.
- a suitable protecting group for a hydroxy group is, for example, an acyl group, for example an alkanoyl group such as acetyl, an aroyl group, for example benzoyl, or an arylmethyl group, for example benzyl.
- the deprotection conditions for the above protecting groups will necessarily vary with the choice of protecting group.
- an acyl group such as an alkanoyl or an aroyl group may be removed, for example, by hydrolysis with a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- a suitable base such as an alkali metal hydroxide, for example lithium or sodium hydroxide.
- an arylmethyl group such as a benzyl group may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- a suitable protecting group for a carboxy group is, for example, an esterifying group, for ex)ample a methyl or an ethyl group which may be removed, for example, by hydrolysis with a base such as sodium hydroxide, or for example a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- a base such as sodium hydroxide
- a t-butyl group which may be removed, for example, by treatment with an acid, for example an organic acid such as trifluoroacetic acid, or for example a benzyl group which may be removed, for example, by hydrogenation over a catalyst such as palladium-on-carbon.
- the protecting groups may be removed at any convenient stage in the synthesis using conventional techniques well known in the chemical art.
- the following assays can be used to measure the effects of the compounds of the present invention as HDAC inhibitors, as inhibitors in vitro of pooled histone deacetylases from nuclear extracts prepared from the human cervical cancer cell line HeLa, as inhibitors in vitro of recombinant human HDAC1 produced in Hi5 insect cells, and as inducers in vitro of Histone H3 acetylation in whole cells.
- HDAC inhibitors were screened against pooled histone deacetylases from nuclear extracts prepared from the human cervical cancer cell line HeLa.
- the deacetylase assays were carried out in a 40 ⁇ l reaction.
- 2.5 ⁇ g of nuclear extract diluted in 15 ⁇ l of reaction buffer 25 mM TrisHCl (pH 8), 137 mM NaCl, 2.7 mM KCl,1 mM MgCl 2
- reaction buffer 25 mM TrisHCl (pH 8), 137 mM NaCl, 2.7 mM KCl,1 mM MgCl 2
- 25 ⁇ M fluor-de-lys substrate (Biomol) diluted in 20 ⁇ l of buffer was then added to the reaction and incubated for one hour at ambient temperature.
- the reaction was stopped by addition of an equal volume (40 ⁇ l) fluor de lys developer (Biomol) containing Trichostatin A at 2 ⁇ M.
- IC 50 values for HDAC enzyme inhibitors were determined by performing dose response curves with individual compounds and determining the concentration of inhibitor producing fifty percent decrease in the maximal signal (no inhibitor control).
- HDAC inhibitors were screened against recombinant human HDAC1 produced in Hi5 insect cells.
- the enzyme was cloned with a FLAG tag at the C-terminal of the gene and affinty purified using Anti-FLAG M2 agarose from SIGMA (A2220).
- the deacetylase assays were carried out in a 50 ⁇ l reaction.
- 75 ng of enzyme diluted in 15 ⁇ l of reaction buffer 25 mM TrisHCl (pH 8), 137 mM NaCl, 2.7 mM KCl,1 mM MgCl 2
- reaction buffer 25 mM TrisHCl (pH 8), 137 mM NaCl, 2.7 mM KCl,1 mM MgCl 2
- 50 ⁇ M fluor-de-lys substrate (Biomol) diluted in 25 ⁇ l of buffer was then added to the reaction and incubated for one hour at ambient temperature.
- the reaction was stopped by addition of an equal volume (50 ⁇ l) fluor de lys developer (Biomol) containing Trichostatin A at 2 ⁇ M.
- IC 50 values for HDAC enzyme inhibitors were determined by performing dose response curves with individual compounds and determining the concentration of inhibitor producing fifty percent decrease in the maximal signal (no inhibitor control).
- Histone H3 acetylation in whole cells using immunohistochemistry and analysis using the Cellomics arrayscan were seeded in 96 well plates at 1 ⁇ 10 4 cells/well, and allowed to adhere overnight. They were treated with inhibitors for 24 hours and then fixed in 1.8% formaldehyde in tris buffered saline (TBS) for one hour. Cells were permeabilized with ice-cold methanol for 5 minutes, rinsed in TBS and then blocked in TBS 3% low-fat dried milk for 90 minutes. Cells were then incubated with polyclonal antibodies specific for the acetylated histone H3 (Upstate #06-599) diluted 1 in 500 in TBS 3% milk for one hour.
- TBS tris buffered saline
- EC 50 values for HDAC inhibitors were determined by performing dose response curves with individual compounds and then determining the concentration of inhibitor producing fifty percent of the maximal signal (reference compound control—Trichostatin A (Sigma)).
- a pharmaceutical composition which comprises a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester or amide thereof, as defined hereinbefore in association with a pharmaceutically-acceptable diluent or carrier.
- composition may be in a form suitable for oral administration, for example as a tablet or capsule, for parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion) as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
- parenteral injection including intravenous, subcutaneous, intramuscular, intravascular or infusion
- sterile solution emulsion
- topical administration as an ointment or cream or for rectal administration as a suppository.
- compositions may be prepared in a conventional manner using conventional excipients.
- the compound of formula (I) will normally be administered to a warm-blooded animal at a unit dose within the range 5-5000 mg per square meter body area of the animal, i.e. approximately 0.1-100 mg/kg, and this normally provides a therapeutically-effective dose.
- a unit dose form such as a tablet or capsule will usually contain, for example 1-250 mg of active ingredient.
- Preferably a daily dose in the range of 1-50 mg/kg is employed.
- the daily dose will necessarily be varied depending upon the host treated, the particular route of administration, and the severity of the illness being treated. Accordingly the optimum dosage may be determined by the practitioner who is treating any particular patient.
- the compounds defined in the present invention are effective cell cycle inhibitors (anti-cell proliferation agents), which property is believed to arise from their HDAC inhibitory properties.
- the compounds of the present invention may be involved in the inhibition of angiogenesis, activation of apoptosis and differentiation. Accordingly the compounds of the present invention are expected to be useful in the treatment of diseases or medical conditions mediated alone or in part by HDAC enzymes, i.e. the compounds may be used to produce a HDAC inhibitory effect in a warm-blooded animal in need of such treatment.
- the compounds of the present invention provide a method for treating the proliferation of malignant cells characterised by inhibition of HDAC enzymes, i.e. the compounds may be used to produce an anti-proliferative effect mediated alone or in part by the inhibition of HDACs.
- a method for producing a HDAC inhibitory effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester or amide thereof, as defined hereinbefore.
- a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester or amide thereof, as defined hereinbefore in the manufacture of a medicament for use in the production of a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal such as man.
- a method for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester or amide thereof, as defined hereinbefore.
- a method of treating cancer in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester or amide thereof, as defined hereinbefore.
- the is provided a method of treating lung cancer, colorectal cancer, breast cancer, prostate cancer, lymphoma or leukaemia, in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester or amide thereof, as defined hereinbefore.
- Cancers that are amenable to treatment with the present invention include oesophageal cancer, myeloma, hepatocellular, pancreatic and cervical cancer, Ewings tumour, neuroblastoma, kaposis sarcoma, ovarian cancer, breast cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, lung cancer [including non small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)], gastric cancer, head and neck cancer, brain cancer, renal cancer, lymphoma and leukaemia.
- NSCLC non small cell lung cancer
- SCLC small cell lung cancer
- a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester or amide thereof, as defined hereinbefore, is provided for use in a method of treating inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastro-intestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflammation of the skin (especially psoriasis, eczema, dermatitis), multiple sclerosis, atherosclerosis, spondyloarthropathies (ankylosing spondylitis, psoriatic arthritis, arthritis connected to ulcerative colitis), AIDS-related neuropathies, systemic lupus erythematosus, asthma, chronic obstructive lung diseases, bronchitis, pleuritis, adult respiratory distress syndrome, sepsis, and acute and chronic hepatitis (either viral, bacterial or toxic).
- inflammation of the joint especially r
- a compound of the formula (I), or a pharmaceutically acceptable salt or in vivo hydrolysable ester or amide thereof, as defined hereinbefore, is provided for use as a medicament in the treatment of inflammation of the joint (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastrointestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), inflammation of the skin (especially psoriasis, eczema, dermatitis), multiple sclerosis, atherosclerosis, spondyloarthropathies (ankylosing spondylitis, psoriatic arthritis, arthritis connected to ulcerative colitis), AIDS-related neuropathies, systemic lupus erythematosus, asthma, chronic obstructive lung diseases, bronchitis, pleuritis, adult respiratory distress syndrome, sepsis, and acute and chronic hepatitis (either viral, bacterial or toxic).
- inflammation of the joint especially r
- the size of the dose required for the therapeutic or prophylactic treatment of a particular cell-proliferation disease will necessarily be varied depending on the host treated, the route of administration and the severity of the illness being treated.
- a unit dose in the range, for example, 1-100 mg/kg, preferably 1-50 mg/kg is envisaged.
- the HDAC inhibitory activity defined hereinbefore may be applied as a sole therapy or may involve, in addition to a compound of the invention, one or more other substances and/or treatments. Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate administration of the individual components of the treatment.
- the other component(s) of such conjoint treatment in addition to the cell cycle inhibitory treatment defined hereinbefore may be: surgery, radiotherapy or chemotherapy.
- Such chemotherapy may include one or more of the following categories of anti-tumour agents:
- a pharmaceutical product comprising a compound of the formula (I) as defined hereinbefore and an additional anti-tumour substance as defined hereinbefore for the conjoint treatment of cancer.
- the compounds of formula (I) and their pharmaceutically acceptable salts or in vivo hydrolysable esters or amides thereof are also useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of cell cycle activity in laboratory animals such as cats, dogs, rabbits, monkeys, rats and mice, as part of the search for new therapeutic agents.
- the definition of the compound of formula (I) includes the compounds N-(2-amino-6-hydroxyphenyl)-4-(1-methylhomopiperazin-4-yl)benzamide; N-(2-amino-6-methylphenyl)-4-(1-methylhomopiperazin-4-yl)benzamide; N-(2-aminophenyl)-4-(1-t-butoxycarbonylhomopiperazin-4-yl)benzamide; and N-(2-aminophenyl)-4-(1-methylhomopiperazin-4-yl)benzamide.
- N-(2-t-Butoxycarbonylaminophenyl)-4-pyridin-4-ylbenzamide (Method 1; 100 mg, 0.26 mmol), 1,4-dioxane (2 ml) and a 4M solution of hydrogen chloride in dioxane (2 ml) were stirred at ambient temperature for approximately 20 hours.
- N-(2-Aminophenyl)-4-piperidin-4-ylbenzamide (Example 5, 48 mg, 0.16 mmol) was stirred and dissolved in anhydrous DMF (2 ml) at ambient temperature. Potassium carbonate (23 mg, 0.16 mmol) was added followed by iodomethane (0.01 ml, 0.16 mmol) and the mixture stirred for 3 hours. The reaction mixture was diluted with water (20 ml) and extracted with ethyl acetate.
- N-(2-t-Butoxycarbonylaminophenyl)-4-(1-methylpiperazin-4-yl)benzamide (Method 16, 196 mg, 0.48 mmol) was dissolved in a 1M solution of hydrogen chloride in diethyl ether (7.2 ml, 7.2 mmol) and stirred at ambient temperature for 24 hours. The resultant precipitate was collected by filtration and washed with diethyl ether. To the solid was added a 2M solution of aqueous sodium hydroxide (5 ml) and the mixture extracted with ethyl acetate.
- N-(2-Aminophenyl)-4-[2-(3-morpholinoaminopropyl)-pyrimidin-6-yl]benzamide trihydrochloride (Method 19, 28 mg, 0.052 mmol) was dissolved in water (2 ml) and basified to pH 10 by the of addition of 28% aqueous ammonium hydroxide solution (2 drops). The resultant precipitate was collected by filtration and dried under vacuum at 40° C.
- N-(2-Aminophenyl)-4-[2-(3-morpholinoaminoethyl)-pyrimidin-6-yl]benzamide trihydrochloride (Method 24, 22 mg, 0.042 mmol) was reacted in an analogous manner to that described for Example 7 to afford the title compound as a pale yellow solid (12 mg, 68%); NMR (DMSO-d 6 ): 2.45 (m, 4H), 2.54 (m, 2H), 3.51 (m, 2H), 3.59 (m, 4H), 4.92 (s, 2H), 6.62 (t, 1H), 6.80 (d, 1H), 6.99 (t, 1H), 7.07 (t, 1H), 7.20 (d, 1H), 7.24 (d, 1H), 8.11 (d, 2H), 8.23 (d, 2H), 8.40 (d, 1H), 9.74 (s, 1H); Mass Spectrum: M+H + 419.
- N-(2-t-butoxycarbonylaminophenyl)-4-[5-(piperidin-1-ylmethyl)-1,3-thiazol-2-yl]benzamide (Method 51, 271 mg, 0.54 mmol) was suspended in 1,4 dioxane (4 ml) and a 4M solution of hydrogen chloride in 1,4-dioxane (4 ml) added. The reaction mixture was stirred at ambient temperature for 17 hours. The resultant precipitate was collected by filtration, washed with diethyl ether and air dried to yield the title compound as its hydrochloride salt.
- N-(2-aminophenyl)-4-piperidine-4-ylbenzamide (Example 5, 162 mg, 0.55 mmol), potassium carbonate (153 mg, 1.1 mmol) and (2-fluorophenyl)-3-bromopropionamide (149 mg, 0.61 mmol) in DMF (5 ml) were stirred at ambient temperature for approximately 20 hours. The mixture was concentrated in vacuo and the residue partitioned between water and ethyl acetate. The organic layer was separated, dried over magnesium sulfate and evaporated.
- N-(2-aminophenyl)-4-piperidin-4-ylbenzamide (Example 5, 30 mg, 0.10 mmol) was stirred and dissolved in N,N-dimethylacetamide (2 ml) and acetic anhydride (0.011 ml, 0.11 mmol) added. The reaction was stirred at ambient temperature for 1 hour and then partitioned between water and ethyl acetate.
- the starting materials for the above examples are either commercially available or are readily prepared by standard methods from known materials.
- the following reactions are illustrations but not limitations of the preparation of some of the starting materials used in the above reactions.
- N-(2-t-Butoxycarbonylaminophenyl)-4-bromobenzamide (Method 14; 136 mg, 0.33 mmol), pyridine-4-boronic acid (48 mg, 0.39 mmol), tetrakis(triphenylphosphine)palladium (5 mg, 0.005 mmol), THF (2 ml) and a saturated aqueous solution of sodium hydrogen carbonate (2 ml) were stirred at 55° C. under an atmosphere of argon for 96 hours. The cooled mixture was partitioned between ethyl acetate and water. The organics were washed with brine, dried over magnesium sulfate, filtered and evaporated, to give the title compound (103 mg, 80%), which was used without further purification; Mass Spectrum: M+H + 390.
- N-(2-t-Butoxycarbonylaminophenyl)-4-bromobenzamide (Method 14; 200 mg, 0.5 mmol), 8-quinoline boronic acid (104 mg, 0.6 mmol), tetrakis(triphenylphosphine)palladium (8 mg, 0.007 mmol), 1,2-dimethoxyethane (3 ml) and a saturated aqueous solution of sodium hydrogen carbonate (3 ml) were stirred at 80° C. under an atmosphere of argon for 20 hours. The mixture was allowed to cool before being partitioned between ethyl acetate and water. The organics were washed with brine, dried over magnesium sulfate, filtered and evaporated.
- N-(2-t-Butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13; 132 mg, 0.3 mmol), 2-bromopyridine (40 mg, 0.25 mmol), tetrakis(triphenylphosphine)palladium (4 mg, 0.004 mmol), 1,2-dimethyoxyethane (1.5 ml) and a saturated aqueous solution of sodium hydrogen carbonate (1.5 ml) were stirred at 80-85° C. under an atmosphere of argon for 24 hours. The mixture was allowed to cool before being partitioned between ethyl acetate and water. The organics were separated, washed with brine, dried over magnesium sulfate, filtered and evaporated to yield the title compound (86 mg, 74%) which was used in the next reaction without further purification; Mass Spectrum: M+H + 390.
- N-(2-t-Butoxycarbonylaminophenyl)-4-bromobenzamide (Method 14; 3.0 g, 7.7 mmol) was added to a solution of bis-pinacolato diboron (2.3 g, 9.2 mmol), 1,1′-bis(diphenylphosphino)ferrocenedichloropalladium (II) chloride (157 mg, 0.19 mmol) and potassium acetate (2.3 g, 23 mmol) in DMF (48 ml) at 80° C. under an atmosphere of argon for 20 hours. The mixture was allowed to cool and the solvent removed in vacuo. The residue was partitioned between ethyl acetate and water.
- 4-(4,6-Dimethoxy-1,3,5-triazinyl-2-yl)-4-methylmorpholinium chloride was prepared according to the literature procedure described in Kunishima, M., Kawachi, C., Morita, J., Terao, K., Iwasaki, F., Tani, S., Tetrahedron, 1999, 55, 13159-13170.
- N-(2-t-Butoxyaminophenyl)-4-[2-(3-morpholinoaminopropyl)-pyrimidin-6-yl]benzamide (Method 20, 64 mg, 0.120 mmol) was suspended in 1,4 dioxane (1.5 ml) and a 4M solution of hydrogen chloride in 1,4-dioxane (1 ml) added. The reaction mixture was stirred at ambient temperature for 64 hours. The reaction mixture was diluted with diethyl ether, and the resultant precipitate was collected by filtration, washed with diethyl ether and air dried, to yield the title compound (as its hydrochloride salt) as an off white solid (62 mg, 95%); Mass Spectrum: M+H + 433.
- N-(2-t-Butoxyaminophenyl)-4-(2-methylsulfonyl-pyrimidin-6-yl)benzamide (Method 21, 62.5 mg, 0.133 mmol) was dissolved in a mixture of THF (2 ml) and N,N-dimethylacetamide (2 ml) and N-(3-aminopropyl)morpholine (60 ⁇ l, 0.411 mmol) added. The reaction mixture was heated to 50° C. and stirred for 2 hours. The reaction mixture was then cooled and solvents removed under reduced pressure.
- N-(2-t-Butoxyaminophenyl)-4-(2-thiomethyl-pyrimidin-6-yl)benzamide (Method 22, 140 mg, 0.32 mmol) was dissolved in methanol (8 ml) and a small amount of ethyl acetate, followed by a solution of Oxone® (630 mg, 1.02 mmol) in water (4 ml). The resultant suspension was stirred at ambient temperature for 1 hour before being partitioned between ethyl acetate and a mixture of water and saturated sodium bicarbonate. The organic phase was separated and the aqueous phase extracted with further aliquots of ethyl acetate. The combined organic extracts were washed with brine and dried over magnesium sulfate.
- N-(2-t-Butoxyaminophenyl)-4-(2-methylsulfonyl-pyrimidin-6-yl)benzamide (Method 21, 62.5 mg, 0.133 mmol) was reacted with N-(2-aminoethyl)morpholine (60 ⁇ l, 0.457 mmol) in an analogous manner to that described in method 20 to yield the title compound as a pale yellow solid (66 mg, 96%);
- N-(2-t-butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13, 1.20 g, 2.74 mmol) was reacted with 2-methyl-5-bromopyridine (505 mg, 2.94 mmol).
- N-(2-t-butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13, 3.9 g, 8.9 mmol) was reacted with 2,4-dichloropyrimidine (3.06 g, 20.5 mmol).
- N-(2-t-butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13, 4.0 g, 9.12 mmol), 5-bromo-2-chloropyrimidine (1.76 g, 9.12 mmol), tetrakis(triphenylphosphine)palladium (527 mg, 0.46 mmol), 1,2-dimethoxyethane (40 ml) and a saturated aqueous solution of sodium hydrogen carbonate (40 ml) were stirred at 80° C. under an atmosphere of argon for 18 hours. The cooled mixture was concentrated under reduced pressure.
- N-(2-t-butoxycarbonylaminophenyl)-4-[2-(methylsulfonyl)pyrimidin-4-yl]benzamide (Method 21, 1.097 g, 2.34 mmol) was reacted to give the title compound as its hydrochloride salt (1.01 g, 98%); NMR Spectrum: (DMSO-d 6 ) 3.53 (s, 3H), 7.31 (m, 3H), 7.52 (d, 1H), 8.30 (d, 2H), 8.48 (d, 2H), 8.53 (d, 1H), 9.20 (d, 1H), 10.56 (s, 1H); Mass Spectrum: M+H + 369.
- N-(2-t-butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13, 219 mg, 0.5 mmol) was reacted with (2-chloro-1,3-thiazol-5-yl)methyl cyclohexylcarbamate (138 mg, 0.5 mmol).
- the crude residue was stirred in ethyl acetate for 16 hours before being filtered, mixed with water and the aqueous removed using a Varian Chem Elut Column (CE1010).
- the resulting solution was concentrated and purified by flash chromatography on silica, eluting with methanol/dichloromethane (0-30%) to give the title compound; Mass Spectrum: M+H + 551.
- N-(2-t-butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13, 219 mg, 0.5 mmol) was reacted with 4-(5-bromothien-2-yl)-2-(methylthio)pyrimidine (145 mg, 0.5 mmol).
- the crude residue stirred in ethyl acetate/water for 1 hour before being filtered, and the aqueous removed using a Varian Chem Elut Column (CE1010).
- the resulting solution was concentrated and recrystallised from methanol to give the title compound; Mass Spectrum: M+H + -Boc 463.
- N-(2-t-butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13, 219 mg, 0.5 mmol) was reacted with (2-chloro-1,3-thiazol-5-yl)methyl N-phenylcarbamate (136 mg, 0.5 mmol).
- the crude residue stirred in ethyl acetate/water for 16 hours before being filtered, and the aqueous removed using a Varian Chem Elut Column (CE1010).
- the resulting solution was concentrated and purified by flash chromatography on silica, eluting with methanol/dichloromethane (0-30%) to give the title compound; Mass Spectrum: M+H + -Boc 489.
- N-(2-t-butoxycarbonylaminophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide (Method 13) (318 mg, 0.72 mmol) was added followed by tetrakis(triphenylphosphine)palladium (100 mg, 0.09 mmol) and the mixture stirred at 80° C. for 18 hours. The cooled mixture was partitioned between ethyl, acetate and water. The organic phase was separated, then washed with water and dried over magnesium sulfate, filtered and evaporated.
- 1,2,3,4-tetrahydroquinoline (10 g, 75 mmol) was dissolved in benzene (40 ml) and cooled to 10° C.
- a solution of bromoacetyl bromide (16 g, 80 mmol) in benzene (40 ml) was added dropwise over 1 hour. The mixture was stirred for a further 15 minutes.
- a 2M aqueous solution of sodium hydroxide (500 ml) was added. The organic layer was separated, washed with water (100 ml), dried over magnesium sulfate and evaporated to afford the crude product as an oil.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/211,510 US20090029991A1 (en) | 2002-04-05 | 2008-09-16 | Benzamide derivatives useful as histone deacetylase inhibitors |
US12/879,367 US8247562B2 (en) | 2002-04-05 | 2010-09-10 | Benzamide derivatives useful as histone deacetylase inhibitors |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0207863A GB0207863D0 (en) | 2002-04-05 | 2002-04-05 | Benzamide derivatives |
GB0207863.2 | 2002-04-05 | ||
GB0229930.3 | 2002-12-21 | ||
GB0229930A GB0229930D0 (en) | 2002-12-21 | 2002-12-21 | Benzamide derivatives |
PCT/GB2003/001442 WO2003087057A1 (en) | 2002-04-05 | 2003-04-02 | Benzamide derivatives useful as histone deacetylase inhibitors |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/211,510 Continuation US20090029991A1 (en) | 2002-04-05 | 2008-09-16 | Benzamide derivatives useful as histone deacetylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
US20050171103A1 true US20050171103A1 (en) | 2005-08-04 |
Family
ID=29252435
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/509,941 Abandoned US20050171103A1 (en) | 2002-04-05 | 2003-04-02 | Benzamide derivatives useful as histone deacetylase inhibitors |
US12/211,510 Abandoned US20090029991A1 (en) | 2002-04-05 | 2008-09-16 | Benzamide derivatives useful as histone deacetylase inhibitors |
US12/879,367 Expired - Fee Related US8247562B2 (en) | 2002-04-05 | 2010-09-10 | Benzamide derivatives useful as histone deacetylase inhibitors |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/211,510 Abandoned US20090029991A1 (en) | 2002-04-05 | 2008-09-16 | Benzamide derivatives useful as histone deacetylase inhibitors |
US12/879,367 Expired - Fee Related US8247562B2 (en) | 2002-04-05 | 2010-09-10 | Benzamide derivatives useful as histone deacetylase inhibitors |
Country Status (26)
Country | Link |
---|---|
US (3) | US20050171103A1 (el) |
EP (1) | EP1495002B1 (el) |
JP (1) | JP4471665B2 (el) |
KR (1) | KR101066508B1 (el) |
CN (2) | CN1642915A (el) |
AR (1) | AR039257A1 (el) |
AU (1) | AU2003217054B2 (el) |
BR (1) | BR0308875A (el) |
CA (1) | CA2480356C (el) |
CY (1) | CY1113483T1 (el) |
DK (1) | DK1495002T3 (el) |
EG (1) | EG25655A (el) |
ES (1) | ES2392963T3 (el) |
HK (1) | HK1071359A1 (el) |
IL (2) | IL164373A0 (el) |
IS (1) | IS2895B (el) |
MX (1) | MXPA04009689A (el) |
MY (1) | MY142177A (el) |
NO (1) | NO330119B1 (el) |
NZ (1) | NZ535143A (el) |
PL (1) | PL372967A1 (el) |
PT (1) | PT1495002E (el) |
RU (1) | RU2376287C2 (el) |
SI (1) | SI1495002T1 (el) |
TW (1) | TWI319387B (el) |
WO (1) | WO2003087057A1 (el) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070249051A1 (en) * | 2006-01-25 | 2007-10-25 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
WO2009016088A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
US20090130689A1 (en) * | 2005-06-07 | 2009-05-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method useful for detecting encephalopathies |
US20100075942A1 (en) * | 2005-01-15 | 2010-03-25 | Astrazeneca Ab | N-phenyl-4-pyridin-2-yl-benzamide derivatives as histone deacylase (hdac) inhibitors for the treatment of cancer |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20100317739A1 (en) * | 2007-12-14 | 2010-12-16 | Brown Milton L | Histone deacetylase inhibitors |
Families Citing this family (145)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
WO2003024448A2 (en) | 2001-09-14 | 2003-03-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
AU2003216322A1 (en) | 2002-02-15 | 2003-09-09 | Rigel Pharmaceuticals, Inc. | Inhibitors of tubulin polymerization |
DE60321667D1 (en) | 2002-03-13 | 2008-07-31 | Janssen Pharmaceutica Nv | Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase |
EP1485364B1 (en) | 2002-03-13 | 2009-03-11 | Janssen Pharmaceutica N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
CA2495354A1 (en) * | 2002-08-20 | 2004-03-04 | Yamanouchi Pharmaceutical Co., Ltd. | An agent for inhibiting articular cartilage extracellular matrix degradation |
CN1856489A (zh) | 2003-09-22 | 2006-11-01 | 欧洲凯尔特公司 | 用于治疗疼痛的苯甲酰胺化合物 |
AU2004276337B2 (en) | 2003-09-24 | 2009-11-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
TW200533357A (en) * | 2004-01-08 | 2005-10-16 | Millennium Pharm Inc | 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases |
US20080275062A1 (en) * | 2004-01-30 | 2008-11-06 | David Harold Drewry | Chemical Compounds |
US7253204B2 (en) | 2004-03-26 | 2007-08-07 | Methylgene Inc. | Inhibitors of histone deacetylase |
AU2005225471B2 (en) * | 2004-03-26 | 2011-05-12 | Methylgene Inc. | Inhibitors of histone deacetylase |
MX2007001120A (es) | 2004-07-28 | 2007-03-15 | Janssen Pharmaceutica Nv | Derivados de indolil alquil sustituidos como nuevos inhibidores de la histona desacetilasa. |
RS51189B (sr) | 2004-07-28 | 2010-10-31 | Janssen Pharmaceutica N.V. | Supstituisani derivati propenil piperazina kao novi inhibitori histonske deacetilaze |
AR050926A1 (es) * | 2004-09-03 | 2006-12-06 | Astrazeneca Ab | Derivados de benzamida como inhibidores de la histonadesacetilasa(hdac) |
CA2584307A1 (en) * | 2004-10-15 | 2006-06-15 | Bayer Pharmaceuticals Corporation | Indane amides with antiproliferative activity |
US20090018145A1 (en) * | 2004-10-19 | 2009-01-15 | Compass Pharmaceuticals Llc | Compositions and their use as anti-tumor agents |
GB0427758D0 (en) * | 2004-12-18 | 2005-01-19 | Astrazeneca Ab | Novel benzamide compounds |
JP5124285B2 (ja) | 2004-12-28 | 2013-01-23 | キネックス ファーマシューティカルズ, エルエルシー | 細胞増殖性障害を処置する組成物および方法 |
US7968574B2 (en) | 2004-12-28 | 2011-06-28 | Kinex Pharmaceuticals, Llc | Biaryl compositions and methods for modulating a kinase cascade |
GB0501146D0 (en) * | 2005-01-20 | 2005-02-23 | Astrazeneca Ab | Novel benzamide derivatives |
EP2946810A1 (en) | 2005-02-03 | 2015-11-25 | TopoTarget UK Limited | Combination therapy using an HDAC inhibitor and Vincristine for treating cancer |
CN101163690A (zh) | 2005-04-20 | 2008-04-16 | 默克公司 | 苯并噻吩异羟肟酸衍生物 |
EP1874295A4 (en) | 2005-04-20 | 2009-08-12 | Merck & Co Inc | benzothiophene |
WO2006115833A1 (en) | 2005-04-20 | 2006-11-02 | Merck & Co., Inc. | Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions |
GB0509225D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Inhibitors of enzymatic activity |
GB0509223D0 (en) | 2005-05-05 | 2005-06-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
EP1719508A1 (en) * | 2005-05-06 | 2006-11-08 | Yih-Lin Chung | Use of histone deacetylase inhibitors for the prevention or treatment of joint destruction |
KR101329437B1 (ko) | 2005-05-13 | 2013-11-14 | 토포타겟 유케이 리미티드 | Hdac 억제제의 약학 제형 |
WO2006122926A1 (en) | 2005-05-18 | 2006-11-23 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
EP1896395B1 (en) | 2005-06-24 | 2015-07-15 | Merck Sharp & Dohme Corp. | Modified malonate derivatives |
JP2009501721A (ja) * | 2005-07-12 | 2009-01-22 | アカディア ファーマシューティカルズ インコーポレイテッド | レチノイン酸受容体における活性を伴う化合物 |
GB0521244D0 (en) * | 2005-10-19 | 2005-11-30 | Astrazeneca Ab | Benzamide compounds |
US7884105B2 (en) | 2005-10-27 | 2011-02-08 | Janssen Pharmaceutica, N.V. | Squaric acid derivatives as inhibitors of histone deacetylase |
JP2009514858A (ja) | 2005-11-03 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | アリール−ピラゾリルモチーフを有するヒストンデアセチラーゼ阻害剤 |
AU2006313517B2 (en) | 2005-11-10 | 2013-06-27 | Topotarget Uk Limited | Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent |
AR057579A1 (es) | 2005-11-23 | 2007-12-05 | Merck & Co Inc | Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac) |
GB0526351D0 (en) * | 2005-12-23 | 2006-02-01 | Astrazeneca Ab | Novel benzamide derivatives |
GB0526352D0 (en) * | 2005-12-23 | 2006-02-01 | Astrazeneca Ab | Benzamide derivatives |
ATE539073T1 (de) | 2006-01-19 | 2012-01-15 | Janssen Pharmaceutica Nv | Heterocyclylalkylderivate als neue inhibitoren von histondeacetylase |
PL1981874T3 (pl) | 2006-01-19 | 2009-10-30 | Janssen Pharmaceutica Nv | Pochodne aminofenylowe jako nowe inhibitory deacetylazy histonowej |
WO2007082874A1 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
US8101616B2 (en) | 2006-01-19 | 2012-01-24 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
EP1981875B1 (en) | 2006-01-19 | 2014-04-16 | Janssen Pharmaceutica N.V. | Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase |
CN101370791B (zh) | 2006-01-19 | 2012-05-02 | 詹森药业有限公司 | 作为组蛋白脱乙酰基酶抑制剂的吡啶和嘧啶衍生物 |
CA2642813A1 (en) | 2006-02-28 | 2007-09-07 | Merck & Co., Inc. | Inhibitors of histone deacetylase |
TW200740769A (en) | 2006-03-16 | 2007-11-01 | Astrazeneca Ab | Novel process |
JP5554988B2 (ja) | 2006-04-07 | 2014-07-23 | メチルジーン インコーポレイテッド | ヒストンデアセチラーゼの阻害剤 |
CA2649861A1 (en) | 2006-04-26 | 2007-11-08 | Merck & Co., Inc. | Disubstituted aniline compounds |
CA2651681A1 (en) | 2006-05-18 | 2007-11-29 | Merck & Co., Inc. | Aryl-fused spirocyclic compounds |
AU2007265373B2 (en) | 2006-06-29 | 2013-02-21 | Atnx Spv, Llc | Biaryl compositions and methods for modulating a kinase cascade |
EP1889830A1 (en) * | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
EP2049124A4 (en) | 2006-07-20 | 2010-02-10 | Merck & Co Inc | PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER |
GB0619753D0 (en) | 2006-10-06 | 2006-11-15 | Chroma Therapeutics Ltd | Enzyme inhibitors |
KR20090087013A (ko) | 2006-10-30 | 2009-08-14 | 크로마 데러퓨릭스 리미티드 | 히스톤 탈아세틸효소의 억제제로서 히드록사메이트 |
US7939529B2 (en) | 2007-05-17 | 2011-05-10 | Kinex Pharmaceuticals, Llc | Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof |
US7935697B2 (en) | 2006-12-28 | 2011-05-03 | Kinex Pharmaceuticals, Llc | Compositions for modulating a kinase cascade and methods of use thereof |
TWI457336B (zh) | 2006-12-28 | 2014-10-21 | Kinex Pharmaceuticals Llc | 調節激酶級聯之組成物及方法 |
US8030344B2 (en) | 2007-03-13 | 2011-10-04 | Methylgene Inc. | Inhibitors of histone deacetylase |
JP2008266322A (ja) | 2007-03-28 | 2008-11-06 | Santen Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤 |
CA2687912C (en) | 2007-06-08 | 2015-11-03 | Janssen Pharmaceutica N.V. | Piperidine/piperazine derivatives |
RU2470017C2 (ru) | 2007-06-08 | 2012-12-20 | Янссен Фармацевтика Н.В. | Производные пиперидина/пиперазина |
JO2972B1 (en) | 2007-06-08 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Piperidine / piperazine derivatives |
WO2009002495A1 (en) | 2007-06-27 | 2008-12-31 | Merck & Co., Inc. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
JP2010531358A (ja) | 2007-06-27 | 2010-09-24 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体 |
US8124605B2 (en) | 2007-07-06 | 2012-02-28 | Kinex Pharmaceuticals, Llc | Compositions and methods for modulating a kinase cascade |
CA2700173C (en) | 2007-09-25 | 2016-10-11 | Topotarget Uk Limited | Methods of synthesis of certain hydroxamic acid compounds |
US8476289B2 (en) | 2008-03-27 | 2013-07-02 | Janssen Pharmaceutica Nv | Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylace |
JP5579170B2 (ja) | 2008-06-05 | 2014-08-27 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Dgat阻害剤とppar作動薬を含有する薬剤組み合わせ物 |
ES2620027T3 (es) | 2008-09-03 | 2017-06-27 | Biomarin Pharmaceutical Inc. | Composiciones que incluyen derivados del ácido 6-aminohexanoico como inhibidores de HDAC |
EP2370424A1 (en) | 2008-11-10 | 2011-10-05 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
DK3354650T3 (da) | 2008-12-19 | 2022-05-30 | Vertex Pharma | Forbindelser der er nyttige som inhibitorer af ATR-kinase |
EP2221053A1 (de) * | 2009-02-20 | 2010-08-25 | Albert-Ludwigs-Universität Freiburg | Pharmazeutische Zusammensetzung enthaltend Hemmstoffe der Proteinmethyltransferase I und deren Verwendung zur Behandlung von Tumorerkrankungen |
GB0903480D0 (en) | 2009-02-27 | 2009-04-08 | Chroma Therapeutics Ltd | Enzyme Inhibitors |
EP2421368A4 (en) * | 2009-04-20 | 2013-01-09 | Inst Oneworld Health | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING PYRIDAZINE SULFONAMIDE DERIVATIVES |
CN101906076B (zh) * | 2009-06-04 | 2013-03-13 | 深圳微芯生物科技有限责任公司 | 作为蛋白激酶抑制剂和组蛋白去乙酰化酶抑制剂的萘酰胺衍生物、其制备方法及应用 |
US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
RU2012112151A (ru) * | 2009-09-03 | 2013-10-10 | Аллерган, Инк. | Соединения как модуляторы тирозинкиназы |
SG182401A1 (en) | 2010-01-13 | 2012-08-30 | Tempero Pharmaceuticals Inc | Compounds and methods |
JP2013517281A (ja) | 2010-01-13 | 2013-05-16 | テンペロ、ファーマシューティカルズ、インコーポレイテッド | 化合物及び方法 |
WO2011129936A2 (en) | 2010-04-16 | 2011-10-20 | Kinex Pharmaceuticals, Llc | Compositions and methods for the prevention and treatment of cancer |
WO2011143425A2 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
AU2011253021A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of ATR kinase |
JP2013529200A (ja) | 2010-05-12 | 2013-07-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
JP2013526538A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2569289A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Pyrazines useful as inhibitors of atr kinase |
AU2011253025A1 (en) | 2010-05-12 | 2012-11-29 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
MX2013000103A (es) | 2010-06-23 | 2013-06-13 | Vertex Pharma | Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art. |
US20130310379A1 (en) * | 2010-11-19 | 2013-11-21 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2680694B1 (en) | 2011-02-28 | 2019-01-02 | BioMarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
KR20140027974A (ko) | 2011-04-05 | 2014-03-07 | 버텍스 파마슈티칼스 인코포레이티드 | Tra 키나제의 억제제로서 유용한 아미노피라진 화합물 |
JP6240063B2 (ja) | 2011-04-28 | 2017-11-29 | ザ ブロード インスティテュート, インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
EP2723745A1 (en) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
GB201111630D0 (en) * | 2011-07-07 | 2011-08-24 | Cancer Rec Tech Ltd | Novel compounds and their use |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2013049720A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8846686B2 (en) | 2011-09-30 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP6162126B2 (ja) | 2011-09-30 | 2017-08-23 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
SG11201401093WA (en) | 2011-09-30 | 2014-04-28 | Vertex Pharma | Processes for making compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
US8846918B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用なピラジン化合物 |
WO2013075084A1 (en) | 2011-11-18 | 2013-05-23 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | METHYLATION MODIFICATION ENZYME MODULATORS, COMPOSITIONS AND USES THEREOF |
WO2013078320A1 (en) * | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
US9045493B2 (en) * | 2012-02-09 | 2015-06-02 | Merck Patent Gmbh | Furo[3,2-b]- and thieno[3,2-b]pyridin derivatives |
EP2812001B1 (en) | 2012-02-10 | 2017-06-14 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
HUE035253T2 (en) | 2012-04-05 | 2018-05-02 | Vertex Pharma | Compounds and combination therapies useful as inhibitors of ATR kinase |
US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
EP2877444B1 (en) * | 2012-07-27 | 2020-09-02 | The Broad Institute, Inc. | Inhibitors of histone deacetylase |
ITRM20120405A1 (it) | 2012-08-09 | 2014-02-10 | C N C C S Scarl Collezione Naziona Le Dei Compost | Compounds for use in the treatment of disorders that are ameliorated by inhibition of hdac |
CN109999040A (zh) | 2012-08-30 | 2019-07-12 | 阿西纳斯公司 | 蛋白质酪氨酸激酶调节剂 |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
EP2909202A1 (en) | 2012-10-16 | 2015-08-26 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
HUE052808T2 (hu) | 2012-12-07 | 2021-05-28 | Vertex Pharma | Pirazolo[1,5-A]pirimidinek alkalmazása ATR kináz inhibítorként, rákos megbetegedések kezelésére |
RU2665554C2 (ru) | 2013-03-15 | 2018-08-31 | Байомарин Фармасьютикал Инк. | Ингибиторы hdac |
EP2970286A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase |
US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
EP3033334A1 (en) | 2013-08-15 | 2016-06-22 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
ES2862126T3 (es) * | 2013-10-10 | 2021-10-07 | Acetylon Pharmaceuticals Inc | Compuestos de pirimidín-hidroxiamida como inhibidores de histona desacetilasa |
RS59679B1 (sr) | 2013-12-06 | 2020-01-31 | Vertex Pharma | Jedinjenje 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-karboksamida korisno kao inhibitor atr kinaze, njegovo dobijanje, različiti čvrsti oblici i njegovi radioaktivno obeleženi derivati |
SI3152212T1 (sl) | 2014-06-05 | 2020-06-30 | Vertex Pharmaceuticals Inc. | Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike |
RS59054B1 (sr) | 2014-06-17 | 2019-08-30 | Vertex Pharma | Postupak za lečenje raka korišćenjem kombinacije chk1 i atr inhibitora |
MX2017000307A (es) | 2014-07-07 | 2017-11-23 | Acetylon Pharmaceuticals Inc | Tratamiento de leucemia con inhibidores de histona deacetilasa. |
EP3183248B1 (en) * | 2014-08-21 | 2020-11-11 | Bristol-Myers Squibb Company | Tied-back benzamide derivatives as potent rock inhibitors |
WO2016144702A1 (en) | 2015-03-06 | 2016-09-15 | Pharmakea, Inc. | Lysyl oxidase-like 2 inhibitors and uses thereof |
EP3795568A1 (en) | 2015-03-06 | 2021-03-24 | Pharmakea, Inc. | Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof |
WO2017004522A1 (en) | 2015-07-02 | 2017-01-05 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibtors |
US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
WO2017059357A1 (en) | 2015-09-30 | 2017-04-06 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of dna damaging agents and atr inhibitors |
CN117180280A (zh) | 2016-09-07 | 2023-12-08 | 法玛克亚公司 | 赖氨酰氧化酶样2抑制剂的用途 |
WO2018075598A1 (en) | 2016-10-19 | 2018-04-26 | Constellation Pharmaceuticals, Inc. | Synthesis of inhibitors of ezh2 |
TWI741040B (zh) * | 2016-10-20 | 2021-10-01 | 德商拜耳作物科學公司 | 製備3-烷基硫基-2-氯-n-(1-烷基-1h-四唑-5-基)-4-三氟甲基苯甲醯胺之方法 |
EP3736266A4 (en) * | 2018-01-04 | 2021-01-06 | Peking University Shenzhen Graduate School | COMPOSITION FOR THE SIMULTANEOUS INHIBITION OF LSD1 AND HDAC TARGETS AND THEIR APPLICATION |
US20220306629A1 (en) * | 2018-05-11 | 2022-09-29 | Temple University - Of The Commonwealth System Of Higher Education | Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use |
CN113368114B (zh) * | 2020-03-10 | 2022-04-22 | 四川大学 | 一种吗啉嘧啶类化合物的抗肿瘤应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931215A (en) * | 1973-01-26 | 1976-01-06 | Hoechst Aktiengesellschaft | Benzofuran derivatives |
US3974172A (en) * | 1973-02-09 | 1976-08-10 | Hoechst Aktiengesellschaft | Benzofuran derivatives |
US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2918965A1 (de) * | 1979-05-11 | 1980-11-20 | Bayer Ag | Benzofuranverbindungen sowie deren verwendung als optische aufheller |
IT1232252B (it) * | 1989-02-22 | 1992-01-28 | Rotta Research Lab | Derivati della n fenil benzamide ad attivita' antiulcera ed antiallerica e procedimento per la loro preparazione |
JPH05239069A (ja) * | 1992-02-28 | 1993-09-17 | Canon Inc | 液晶性化合物、これを含む液晶組成物、それを有する液晶素子、それらを用いた表示方法および表示装置 |
JP3354090B2 (ja) | 1996-09-30 | 2002-12-09 | シエーリング アクチエンゲゼルシャフト | 分化誘導剤 |
JPH11269140A (ja) | 1998-03-23 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
JPH11269146A (ja) | 1998-03-24 | 1999-10-05 | Mitsui Chem Inc | 分化誘導剤 |
JP4405602B2 (ja) | 1998-04-16 | 2010-01-27 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ヒストン脱アセチル化酵素阻害剤 |
JPH11335375A (ja) | 1998-05-20 | 1999-12-07 | Mitsui Chem Inc | ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体 |
JP4390024B2 (ja) * | 1999-04-23 | 2009-12-24 | アステラス製薬株式会社 | 新規なジアゼパン誘導体又はその塩 |
PT1233958E (pt) | 1999-11-23 | 2011-09-20 | Methylgene Inc | Inibidores de histona desacetilase |
AU776053B2 (en) * | 2000-03-31 | 2004-08-26 | Astellas Pharma Inc. | Diazepan derivatives or salts thereof |
JP2002161084A (ja) | 2000-11-28 | 2002-06-04 | Sumitomo Pharmaceut Co Ltd | 複素環誘導体 |
WO2003024448A2 (en) * | 2001-09-14 | 2003-03-27 | Methylgene, Inc. | Inhibitors of histone deacetylase |
DE10204115A1 (de) * | 2002-02-01 | 2003-08-07 | Bayer Cropscience Ag | DELTA·1·-Pyrroline |
EP2322160A1 (en) | 2002-03-04 | 2011-05-18 | Merck HDAC Research, LLC | Methods of inducing terminal differentiation |
EP1490013B1 (en) | 2002-03-07 | 2010-02-17 | University Of Delaware | Methods for enhancing oligonucleotide-mediated nucleic acid sequence alteration using compositions comprising hydroxyurea |
JP4725945B2 (ja) | 2002-03-13 | 2011-07-13 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼの新規な阻害剤としてのスルホニルアミノ誘導体 |
EP1485364B1 (en) | 2002-03-13 | 2009-03-11 | Janssen Pharmaceutica N.V. | Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase |
ES2306858T3 (es) | 2002-03-13 | 2008-11-16 | Janssen Pharmaceutica Nv | Derivados de carbonilamino como nuevos inhibidores de las histonadesacetilasas. |
DE60321667D1 (en) | 2002-03-13 | 2008-07-31 | Janssen Pharmaceutica Nv | Piperazinyl-, piperidinyl- und morpholinylderivate als neue inhibitoren von histon-deacetylase |
IL164002A0 (en) | 2002-03-13 | 2005-12-18 | Janssen Pharmaceutica Nv | Sulfonyl-derivatives as novel inhibitors of histone deacetylase |
US20050123397A1 (en) * | 2003-12-03 | 2005-06-09 | Mcardle Nathan J. | Compressor diffuser |
-
2003
- 2003-03-25 TW TW092106629A patent/TWI319387B/zh not_active IP Right Cessation
- 2003-04-02 MX MXPA04009689A patent/MXPA04009689A/es active IP Right Grant
- 2003-04-02 PL PL03372967A patent/PL372967A1/xx unknown
- 2003-04-02 BR BR0308875-8A patent/BR0308875A/pt not_active Application Discontinuation
- 2003-04-02 SI SI200332207T patent/SI1495002T1/sl unknown
- 2003-04-02 CN CNA038074311A patent/CN1642915A/zh active Pending
- 2003-04-02 RU RU2004132844/04A patent/RU2376287C2/ru not_active IP Right Cessation
- 2003-04-02 NZ NZ535143A patent/NZ535143A/en not_active IP Right Cessation
- 2003-04-02 WO PCT/GB2003/001442 patent/WO2003087057A1/en active Application Filing
- 2003-04-02 JP JP2003584013A patent/JP4471665B2/ja not_active Expired - Fee Related
- 2003-04-02 CN CN201010144649A patent/CN101805309A/zh active Pending
- 2003-04-02 EP EP03712442A patent/EP1495002B1/en not_active Expired - Lifetime
- 2003-04-02 DK DK03712442.7T patent/DK1495002T3/da active
- 2003-04-02 KR KR1020047015754A patent/KR101066508B1/ko not_active IP Right Cessation
- 2003-04-02 PT PT03712442T patent/PT1495002E/pt unknown
- 2003-04-02 ES ES03712442T patent/ES2392963T3/es not_active Expired - Lifetime
- 2003-04-02 IL IL16437303A patent/IL164373A0/xx active IP Right Grant
- 2003-04-02 CA CA2480356A patent/CA2480356C/en not_active Expired - Fee Related
- 2003-04-02 US US10/509,941 patent/US20050171103A1/en not_active Abandoned
- 2003-04-02 AU AU2003217054A patent/AU2003217054B2/en not_active Ceased
- 2003-04-03 MY MYPI20031256A patent/MY142177A/en unknown
- 2003-04-04 AR ARP030101185A patent/AR039257A1/es not_active Application Discontinuation
-
2004
- 2004-10-01 IS IS7483A patent/IS2895B/is unknown
- 2004-10-03 IL IL164373A patent/IL164373A/en not_active IP Right Cessation
- 2004-10-03 EG EGNA2004000099 patent/EG25655A/xx active
- 2004-10-19 NO NO20044444A patent/NO330119B1/no not_active IP Right Cessation
-
2005
- 2005-05-17 HK HK05104103.1A patent/HK1071359A1/xx not_active IP Right Cessation
-
2008
- 2008-09-16 US US12/211,510 patent/US20090029991A1/en not_active Abandoned
-
2010
- 2010-09-10 US US12/879,367 patent/US8247562B2/en not_active Expired - Fee Related
-
2012
- 2012-11-22 CY CY20121101133T patent/CY1113483T1/el unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3931215A (en) * | 1973-01-26 | 1976-01-06 | Hoechst Aktiengesellschaft | Benzofuran derivatives |
US3974172A (en) * | 1973-02-09 | 1976-08-10 | Hoechst Aktiengesellschaft | Benzofuran derivatives |
US6174905B1 (en) * | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
US20040087631A1 (en) * | 2002-03-04 | 2004-05-06 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100075942A1 (en) * | 2005-01-15 | 2010-03-25 | Astrazeneca Ab | N-phenyl-4-pyridin-2-yl-benzamide derivatives as histone deacylase (hdac) inhibitors for the treatment of cancer |
US20090130689A1 (en) * | 2005-06-07 | 2009-05-21 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method useful for detecting encephalopathies |
US8435744B2 (en) | 2005-06-07 | 2013-05-07 | Institut National De La Sante Et De La Recherche Medicale | Method useful for detecting encephalopathies |
US7732475B2 (en) | 2005-07-14 | 2010-06-08 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7741494B2 (en) | 2005-07-14 | 2010-06-22 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US20070249051A1 (en) * | 2006-01-25 | 2007-10-25 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
US7816535B2 (en) | 2006-01-25 | 2010-10-19 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
US8729069B2 (en) | 2006-01-25 | 2014-05-20 | Synta Pharmaceuticals Corp. | Tetrahydropyridine, tetrahydroazepine, and dihydropyrrole derivatives for inflammation and immune-related uses |
WO2009016088A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
US20090036420A1 (en) * | 2007-08-02 | 2009-02-05 | Guido Galley | Benzamide derivatives and their use for treating cns disorders |
US20100317739A1 (en) * | 2007-12-14 | 2010-12-16 | Brown Milton L | Histone deacetylase inhibitors |
US8293513B2 (en) | 2007-12-14 | 2012-10-23 | Georgetown University | Histone deacetylase inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8247562B2 (en) | Benzamide derivatives useful as histone deacetylase inhibitors | |
US20050222410A1 (en) | Inhibitors of histone deacetylase | |
US11390618B2 (en) | Inhibitors of cyclin-dependent kinases | |
US7897778B2 (en) | Benzamide compounds | |
US20060035908A1 (en) | Thienopyrimidines useful as Aurora kinase inhibitors | |
US8088761B2 (en) | Enzyme inhibitors | |
US20140080798A1 (en) | Vegfr3 inhibitors | |
US20080119451A1 (en) | Novel Benzamide Derivatives | |
US20100075942A1 (en) | N-phenyl-4-pyridin-2-yl-benzamide derivatives as histone deacylase (hdac) inhibitors for the treatment of cancer | |
US7087606B2 (en) | Water-soluble phenylpyridazine compounds and compositions containing the same | |
SA03240136B1 (ar) | مثبطات انزيم) | |
ZA200407502B (en) | Benzamide derivatives useful as histone deacetylase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ASTRAZENECA AB, SWEDEN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:STOKES, ELAINE SOPHIE ELIZABETH;ROBERTS, CRAIG ANTHONY;WARING, MICHAEL JAMES;REEL/FRAME:016649/0506 Effective date: 20040818 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |